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Antioxidantdressed to mitochondria have been studied to determine if they can decelerate
senescence of organisms. For this purpose, a project has been established with participation of several
research groups from Russia and some other countries. This paper summarizes the ﬁrst results of the project.
A new type of compounds (SkQs) comprising plastoquinone (an antioxidant moiety), a penetrating cation,
and a decane or pentane linker has been synthesized. Using planar bilayer phospholipid membrane (BLM),
we selected SkQ derivatives with the highest permeability, namely plastoquinonyl-decyl-triphenylpho-
sphonium (SkQ1), plastoquinonyl-decyl-rhodamine 19 (SkQR1), and methylplastoquinonyldecyltriphenyl-
phosphonium (SkQ3). Anti- and prooxidant properties of these substances and also of ubiquinonyl-decyl-
triphenylphosphonium (MitoQ) were tested in aqueous solution, detergent micelles, liposomes, BLM,
isolated mitochondria, and cell cultures. In mitochondria, micromolar cationic quinone derivatives were
found to be prooxidants, but at lower (sub-micromolar) concentrations they displayed antioxidant activity
that decreases in the series SkQ1=SkQR1NSkQ3NMitoQ. SkQ1 was reduced by mitochondrial respiratory
chain, i.e. it is a rechargeable antioxidant. Nanomolar SkQ1 speciﬁcally prevented oxidation of mitochondrial
cardiolipin. In cell cultures, SkQR1, a ﬂuorescent SkQ derivative, stained only one type of organelles, namely
mitochondria. Extremely low concentrations of SkQ1 or SkQR1 arrested H2O2-induced apoptosis in human
ﬁbroblasts and HeLa cells. Higher concentrations of SkQ are required to block necrosis initiated by reactive
oxygen species (ROS). In the fungus Podospora anserina, the crustacean Ceriodaphnia afﬁnis, Drosophila, and
mice, SkQ1 prolonged lifespan, being especially effective at early and middle stages of aging. In mammals, the
effect of SkQs on aging was accompanied by inhibition of development of such age-related diseases and traitsl; BLM, planar bilayer phospholipid membrane; C12TPP, dodecyl-triphenylphosphonium; DCF, 2′,7′-dichlorodihydroﬂuor-
ing a methoxy group); DPQ, decyl plastoquinone; FCCP, carbonyl cyanide p-triﬂuoromethoxyphenylhydrazone; MitoQ,
ylphosphonium; NAC, N-acetyl cysteine; ROS, reactive oxygen species; SkQ, compounds composed of plastoquinone or
phonium, rhodamine 19, methylcarnitine, or tributylammonium; SkQ1, compound composed of plastoquinone and decyl-
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438 V.P. Skulachev et al. / Biochimica et Biophysica Acta 1787 (2009) 437–461as cataract, retinopathy, glaucoma, balding, canities, osteoporosis, involution of the thymus, hypothermia,
torpor, peroxidation of lipids and proteins, etc. SkQ1 manifested a strong therapeutic action on some already
pronounced retinopathies, in particular, congenital retinal dysplasia. With drops containing 250 nM SkQ1,
vision was restored to 67 of 89 animals (dogs, cats, and horses) that became blind because of a retinopathy.
Instillation of SkQ1-containing drops prevented the loss of sight in rabbits with experimental uveitis and
restored vision to animals that had already become blind. A favorable effect of the same drops was also
achieved in experimental glaucoma in rabbits. Moreover, the SkQ1 pretreatment of rats signiﬁcantly
decreased the H2O2 or ischemia-induced arrhythmia of the isolated heart. SkQs strongly reduced the
damaged area in myocardial infarction or stroke and prevented the death of animals from kidney ischemia. In
p53−/− mice, 5 nmol/kg×day SkQ1 decreased the ROS level in the spleen and inhibited appearance of
lymphomas to the same degree as million-fold higher concentration of conventional antioxidant NAC. Thus,
SkQs look promising as potential tools for treatment of senescence and age-related diseases.
© 2008 Elsevier B.V. All rights reserved.1 Ref. [22] as well as English versions of our other papers published in Biochemistry
(Moscow) and quoted in this review is available in Internet (see http://protein.bio.
msu.ru/biokhimiya).1. Introduction: hypothesis on mitochondria-targeted
antioxidants as geroprotectors
The free radical hypothesis of Harman [1] is the most frequently
quoted concept on the mechanism of aging. Harman supposed that
oxidation of biopolymers by reactive oxygen species (ROS) plays a
leading role inweakening of vital functions of organismwith age. This
hypothesis has been supported by the ﬁnding that the oxidation level
of DNA, proteins, and lipids increases with aging [2–4]. Such an effect
can be a consequence of an increase with age in ROS production or a
decrease in the antioxidant defense in old age, or simply a result of a
damaging ROS action cumulated proportionally to the organism's age
[2,5,6].
A question arises—what is the source of ROS involved in the aging
processes? The cell contains a set of enzymes that convert O2 to the
primary forms of ROS: superoxide (O2−U) or hydrogen peroxide (H2O2)
[2,7]. However, the activity of all these enzymes is signiﬁcantly lower
than the activity of the mitochondrial respiratory chain. Mitochondria
of a human adult take up about 400 l of O2 per day and convert it to
water by four-electron reduction. If even a small portion of this
amount of O2 is reduced through the chemically simpler one-electron
pathway, this will produce such a O2−U quantity which might greatly
exceeds the abilities of all other mechanisms of ROS generation taken
together.
In the respiratory chain, O2−U is mainly generated in Complexes I
and III. The highest rate of superoxide generation in intact mitochon-
dria in the absence of any inhibitors is observed in Complex I carrying
out reverse transfer of electrons from CoQH2 to NAD+ at the maximal
proton potential (i.e. in the absence of ADP). This rate equal to 1 nmol
O2/mg protein perminute is nearly ﬁvefold higher than the rate of O2−U
production in Complex III under the same conditions [8]. It is 10% of
the respiration rate without ADP (in state 4) and about 1.5% of the
maximal respiration rate in the presence of ADP (in state 3). Such an
amount of superoxide is impressive if one takes into account the high
toxicity of products to which O2−U can be converted, i.e. OHU, HO2U and
ONOO−. In fact, we carry in our mitochondria a potential generator of
very strong toxins that can kill not only single cells but also an entire
organism. Such a catastrophe will be caused not only by the direct
toxic action of ROS, but also as a consequence of triggering apoptosis
and necrosis, which are easily induced by ROS.
Recently, Lambert et al. [9] reported that the lifetime of mammals
and birds is longer the lower is the rate of H2O2 generation by heart
mitochondria during the reverse transfer of electrons from succinate
through Complex I (animals of 12 species very differently system-
atically positioned were studied: frommice to cattle and baboons and
from quails to pigeons). In fact, this observation conﬁrmed earlier
results of Sohal et al. [10] and Barja et al. [4,11] for a smaller number of
warm-blooded species (see Discussion for an interesting exception to
this). No correlationwas shown between lifespan and ROS production
during the forward electron transfer in respiratory chain [9]. More-
over, no indications could be found in the available literature that rateof ROS production by other ROS-generating mechanisms somehow
affects the lifespan.
These observations suggest that protection of cells against
mitochondrial ROS might arrest or at least decelerate aging. As to
the treatment of aging with antioxidants, the literature is rather vast
and ambiguous: from the statement of Ames et al. [12,13] that such a
drug against age is already found to conclusions of Bjelakovic et al.
[14] and Howes [15] about a complete fruitlessness of this approach
and, thus, the erroneousness of Harman's hypothesis.
We think that there are three essential omissions in the studies on
the treatment of aging with antioxidants. (1) If it is necessary to
neutralize just intramitochondrial ROS generated by Complex I
protruding into the mitochondrial matrix, antioxidants speciﬁcally
addressed to mitochondrial interior are required. However, there is
not a single example of a successful use of such antioxidants in
gerontology, described in the literature. Ames et al. [13] employed
tert-butylhydroxylamine as geroprotector and stated that this com-
pound is accumulated bymitochondria. However, not a single piece of
evidence was reported for such a statement. (2) Commonly used
antioxidants (even if they principally can occur, as in the case of
vitamin E, in the mitochondrial membrane) are not speciﬁcally
targeted to this membrane and are also present in other cellular
membranes. This may result is unfavorable side effect due to
involvement of ROS in certain metabolic regulations. Our goal should
be to prevent an age-related increase in the level of intramitochondrial
ROS rather than todischarge anyROS in cells and tissues. (3)All of them
are natural substances, and their excess can be cleared by cellular
enzymes. We are dealing with just such a situation when vitamin E is
used to retard aging. Assuming that aging is programmed [2,5,6,16–20],
it is reasonable to suggest that the organism seeks to realize the aging
program. Therefore, the coming vitamin E (which potentially might be
inhibitory to the aging mechanism) is attacked by cytochrome P450
which is induced in the liver by excess vitamin E [21].
An “ideal” geroprotector operating as an antioxidant has to meet
the following criteria: 1) the antioxidant must not remove ROS
completely, but only their excess generated inside mitochondria by
reverse electron transfer in the respiratory chain; 2) the antioxidant
must not induce cytochrome P450 or any other enzymes in the
organism which is by all means seeking to terminate its ontogenesis
by switching on the aging program [2,5,6,22]1.
The problem of mitochondria-targeted antioxidant might be
solved based on the phenomenon observed in our group jointly
with the group of Dr. E. A. Liberman already in 1969–1970 [23–26].
The case in point is the discovery of so-called penetrating ions, i.e.
synthetic hydrophobic compounds that can easily penetrate across
themitochondrial membrane in spite of the presence of ionized atoms
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sentative of such ions. In this cation, the positive charge on the
phosphorus atom is strongly displaced by three hydrophobic phenyl
residues. As a result, water dipoles cannot be held on the cation and do
not forms an aqueous shell preventing its penetration into the
hydrophobic regions of the membrane. The interior of mitochondria is
the only cell compartment negatively charged relative to its environ-
ment (i.e. to the cytosol) [26,27]; therefore, on entering the cell,
penetrating cations will be accumulated within mitochondria. This
accumulation should be described by the Nernst equation (a 10-fold
gradient at Δψ=60 mV). If in the energized mitochondria Δψ is
∼180 mV, the penetrating cation concentration in the mitochondrial
matrix will be 1000 times higher than in the cytosol.
This consideration led us to an assumption that penetrating cations
can be used by mitochondria as “molecular electric locomotives” to
accumulate uncharged substances attached to these cations [28]. We
used such an idea, trying to explain the role of cationic group of
carnitine in the transport of fatty acid residues into mitochondria
[27,28]. On being electrophoretically concentrated in the inner leaﬂet
of the inner mitochondrial membrane, fatty acyl and carnitine would
be able to act as antioxidant interrupting chain reactions of peroxida-
tion of phospholipids and proteins which constitute this leaﬂet. Such a
suggestion has been conﬁrmed by data obtained in our group by Drs.
Yu. N. Antonenko and A. A. Pashkovskaya. They found that palmitoyl
carnitine prevented a ROS-induced inactivation of gramicidin channel
incorporated into a BLM (the paper in preparation).
At the border of the last two centuries, the principle of “molecular
electric locomotives”was successfully used by Dr. M. P. Murphy for the
addressed delivery into mitochondria of antioxidants thiobutyl [29],
vitamin E [30], and ubiquinone [31]. The so-called MitoQ composed of
ubiquinone and decyl-triphenylphosphonium cation seemed to be
especially promising. MitoQ is obviously more advantageous than
palmitoyl carnitine or cationic derivative of vitamin E because its
reduced form oxidized during the antioxidant process can be
regenerated by accepting electrons from the respiratory chain. In
other words, MitoQ is a rechargeable antioxidant [32]. The experi-
ments of Murphy and his group clearly showed that MitoQ was
accumulated and regenerated within mitochondria and protected
them and also cell cultures against oxidative stress [30–36].
We have conﬁrmed the data of Murphy et al. on the antioxidant
activity of MitoQ but have found that this activity turns to prooxidant
with a rather small increase in theMitoQ concentration [37] (for other
observations about the prooxidant effect of MitoQ, see [33,38,39]).
Thus, in rat heart mitochondria, the C1/2 values for the MitoQ
antioxidant and prooxidant effects were shown to be 0.3 and
0.5 μM, respectively (see below, Fig. 2B). Addition of 1.5–2.5 μM
MitoQ caused such a fast generation of hydrogen peroxide by
mitochondria oxidizing NAD-dependent substrates that its rate was
higher than all recorded values described in the literature, approx-
imating the respiration rate in state 4 [37]. Such a situation makes
risky the use of MitoQ as an antioxidant in practice. Therefore, we
decided to start a search for antioxidants stronger than MitoQ and
with a broader window between the anti- and prooxidant effects.
2. SkQ: synthesis and in vitro studies
The project of using penetrating ions in medical practice was
started in 2003. It was initiated owing to grants from the “Paritet”
charitable foundation (now “Volnoe Delo”) created by Mr. O. V.
Deripaska, a member of the Moscow University Board of Trustees.
In the beginning, demethoxyMitoQ (DMQ), a compound where
CoQ moiety lacks one of CH3–O– groups, has been synthesized. This
was done since it was already known that the nematode Caenorhab-
ditis elegans lives sevenfold longer if it contains a deletion in the genes
encoding (i) the enzyme that converts demethoxyCoQ into ubiqui-
none and (ii) the insulin receptor [40]. It was found that the newsubstance displays an increased difference between the anti- and
prooxidant concentrations compared to MitoQ, but unfortunately this
difference was less pronounced than we would have liked.
We then turned our attention to plastoquinone, an electron carrier
acting instead of ubiquinone in photosynthetic electron transport
chains in chloroplasts of plants and cyanobacteria. Evolution of plants
resulted in a situationwhen ubiquinone involved in the mitochondrial
respiratory chain was substituted by plastoquinone in the chloroplast
chain of the same plant cell, possibly, just because of the better
antioxidant properties of plastoquinone, as shown in chemical
experiments on model systems by Kruk et al. [41] and by our group
[42]. In fact, an oxygen-generating chloroplast is under conditions of
much stronger oxidative stress than a mitochondrion which takes up
oxygen, lowering thereby [O2]. As compared with ubiquinone,
plastoquinone has methyl groups instead of methoxy groups, whereas
the methyl group of ubiquinone is replaced by hydrogen. We have
synthesized plastoquinonyl-decyl-triphenylphosphonium, a com-
pound where the ubiquinone moiety was replaced by plastoquinone.
The new substance was named SkQ1 where Sk is for penetrating
cation (“Skulachev ion”, a term introduced by David Green [43]) and Q
is for plastoquinone.Whereas the anti- and prooxidant concentrations
of MitoQ differed less than twofold (300 and 500 nM), this difference
for SkQ1 was shown to be increased up to 32-fold (25 and 800 nM)
[37] (see below, Fig. 2B).
This result showed that we had found a very effective antioxidant
speciﬁcally addressed to mitochondria and not complicated by danger
of prooxidant effect within a large range of concentrations. In this
connection, we suggested that Mr. Deripaska change the grant to an
investment project aimed at creation of a new type of drugs and
biotechnology products on the basis of SkQ. The proposal was
accepted, and the investment project was started in the spring of 2005.
On searching for the best antioxidant among cationic derivatives of
quinones, a number of substances were synthesized by our chemists
Drs. G. A. Korshunova, N. V. Sumbatyan, and L. S. Yaguzhinsky. It was
taken into account that (1), in contrast to ubiquinone (CoQ),
plastoquinone and another chloroplast electron carrier vitamin K1,
as well as the “professional antioxidant” vitamin E, contain no
methoxy groups, and (2) vitamin K1, vitamin E, and CoQ have in the
ﬁfth position of the quinone ring a methyl group, which is absent in
plastoquinone. As a result, the majority of our quinone derivatives
contained either plastoquinone (SkQ1, SkQ2M, SkQ4, SkQ5, SkQR1) or
methylplastoquinone (SkQ3). For comparison, MitoQ and DMQ
containing, respectively, ubiquinone and demethoxyubiquinone,
were also synthesized. As cations, ﬁrst of all alkyl triphenylpho-
sphonium derivatives were used with the alkyl residue linking the
cation with the quinone being either decyl (SkQ1, see Fig. 1A; SkQ3;
SkQ4; DMQ and MitoQ) or amyl (SkQ5). In some cases, a different
cationwas used. Instead of phosphonium, compounds with an ionized
nitrogen atom were tried: methylcarnitine (SkQ2M), tributylammo-
nium (SkQ4), or Rhodamine 19 (SkQR1, see Fig. 1A). Moreover, a
substance containing two methylene groups instead of plastoquinone
(dodecyltriphenylphosphonium, C12TPP) was synthesized [37].
The new compounds were ﬁrst tested for their ability to penetrate
the model membranes. As experiments on BLMs showed, the gradient
of SkQR1 concentration generated diffusion potential close to
Nernstian (60 mV per tenfold gradient, the “plus” sign in the
compartment with the lower concentration of the cation) in the
range 10−6–10−5 M SkQR1. The same concentrations of SkQ1, SkQ3,
and MitoQ generated Δψ of the right direction but with lower values
than Nernstian (Fig. 1B). The Δψ values for SkQ2M, SkQ4, and SkQ5
weremuch lower thanNernstian [37]. These relationships proved to be
a result of different permeabilities of the studied cation across a BLM.
Direct measurement the rate of transport of the cations from one half-
membrane BLM leaﬂet to the other showed that this rate decreases as
follows: SkQR1NSkQ1NSkQ3NMitoQ [44]. With a cation of low
permeability, there was a risk that the cation diffusion potential will
Fig. 1. Penetrating and anti- and prooxidant properties of SkQs and MitoQ. (A) Formulas of SkQ1H2 and SkQR1H2. (B) Generation of diffusion electric potential on a BLM by SkQs and
MitoQ. In the right compartment, the concentration of the studied compound was 1×10−6 M. In the left compartment, this concentration is indicated by the abscissa. Incubation
mixture, 10 mM Tris–HCl, 10 mM MES, 10 mM KCl, pH 4.0. (C and D) Quenching of AAPH-induced chemiluminescence of luminal by SkQ1H2, SkQ1, MitoQH2 or MitoQ. (E and F)
Autoxidation of SkQ1H2 and MitoQH2 by O2 in aqueous solution. E, Rates of SkQ1 and MitoQ formations from SkQ1H2 and MitoQH2, respectively. F, Rates of O2−
U
formation, TIRON
(sodium 4,5-dihydrobenzene-1,3-disulfonate) being a spin trap. 5 μM SkQ1H2 and MitoQH2. (G) SkQ1 and MitoQ defend gramicidin channels in a BLM against photoinactivation in
the presence of Methylene Blue. Here and in B, the BLM was formed from diphytanoyl phosphatidyl glycerol dissolved in decane. Incubation medium, 100 mM KCl, 10 mM TRIS,
10 mM MES (pH 7.0), 0.5 μM Methylene Blue. (From Antonenko et al. [37]).
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Δψ value below that predicted by the Nernst equation. In principle,
such a difﬁculty might be overcome by increasing concentration of the
penetrating cation. However, at high concentrations all of them showa
detergent activity resulting in damage to the BLM. The problem can be
solved by substituting thick planar phospholipid membrane for BLM.In this case, [SkQ1] could be increased up to 5×10−4 M. Within the
range 5×10−5–5×10−4 M, SkQ1 was shown to generate Nernstian
potential [37]. Based on these ﬁndings, SkQ1 and SkQR1 were chosen
for the majority of further studies.
Anti- and prooxidant activities of the SkQs were tested in model
system, i.e. aqueous solutions, micelles, liposomes and BLM. To
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solution, we studied the effect of these quinones on luminal-mediated
chemiluminescence induced by an azo-initiator, 2, 2′-azobis (2-
amidinopropane) dihydrochloride (AAPH) [45,46]. It is seen (Fig.
1C) that 0.5 μM SkQ1H2 (the reduced form of SkQ1) strongly
decreases chemiluminescence. As for MitoQH2, it showed lower
efﬁciency than SkQH2 (Fig. 1D).
Prooxidant activities of SkQH2 andMitoQH2 in an aqueous solution
are compared in Fig. 1E and F. As measures of such activities, the rates
formation of quinones from corresponding quinols or of reduction O2
to O2−
U
were chosen (Fig. 1E, F). Both methods clearly showed
signiﬁcantly higher prooxidant activity of MitoQH2 compared to the
same concentration of SkQ1H2.
Antioxidant activity of the studied compounds was also analyzed
using an unsaturated fatty acid in detergent micelles. In this case,
peroxidation of methyl ester of linoleate (ML) in Triton X-100 micelles
was followed by measuring O2 consumption with a Clark oxygen
electrode. Antioxidant activity of SkQ1H2 and MitoQH2 was char-
acterized by the rate constant k1 for the reaction between the peroxyl
radical of oxygenated linoleate residue (LO2
U
) and a quinol (QH2):
LO
U
2 þ QH2→LOOHþ QH
U
; ð1Þ
which competes with the reaction of chain propagation (rate constant
k2):
LO
U
2 þ LH→LOOHþ L
U
: ð2Þ
The experiment was started with the measuring the rate of non-
inhibited oxidation of ML, R0. The addition of SkQ1H2 or MitoQH2
resulted in a strong decrease in the rate of oxygen consumption and
the appearance of a pronounced induction period. Importantly, the
oxidized forms of SkQ1 and MitoQ were inactive in this system. As the
antioxidant was consumed, the rate of inhibited oxidation (R)
increased progressively with time, ﬁnally reaching the level of R0.
The time course of changes in R followed the Eq. (3):
F = ln
1 + R= R0
1− R= R0
− R0
R
=
k1R0
k2 ML½ 
t + const: ð3Þ
The k1/k2 value was determined as a slope of an F versus t plot (in
more detail, see [46,47]).
The absolute values of k1 were calculated from k1/k2, assuming
k2=60 M−1 s−1. The values of k1 for SkQ1H2 and MitoQH2 were
found to be 2.2·105 and 0.58·105 M−1 s−1, respectively. Thus, the
reactivity of SkQ1H2 towards LO2
U
was almost four times higher than
that of MitoQH2. This is in line with data obtained for simpler analogs
of SkQ1H2 and MitoQH2, 2,3,5-trimethyl-1,4-hydroquinone and 2,3-
dimetoxy-5-methyl-1,4-hydroquinone [41,47].
In a further series of experiments, we examined the antioxidant
action of SkQ1 and MitoQ in model lipid membranes. First, we used
one of the most conventional methods to assess lipid peroxidation, i.e.
the thiobarbituric acid-reactive substances (TBARS) assay. Lipid
peroxidation in asolectin liposomes was induced by the addition of
100 μM FeSO4, 1 mM ascorbate, and 30 mM tert-butyl-hydroperoxide
(tBOOH). Under these conditions, TBARS formationwas mainly due to
production of malondialdehyde. This process was found to be
substantially slowed in the presence of 10 μM SkQ1H2 [37].
To directly follow the kinetics of oxidative destruction of lipid,we used
C11-BODIPY(581/591), a ﬂuorescent lipid peroxidation probe [48,49]. It
was revealed that the addition of 5 μMFe2+ led to a very strong inhibition
of the BODIPY ﬂuorescence in asolectin liposomes. The Fe2+-induced
ﬂuorescence changes were almost completely prevented in the presence
of 0.5 μM SkQ1H2. Oxidized SkQ1 was without any effect [37].
To model a ROS-caused damage to a membrane protein, a new
method was developed, i.e. ROS sensitivity of the BLM conductance
created by gramicidin D [49]. Tryptophan residues of this channel-
forming peptide were shown to be attacked by ROS, resulting in theinactivation of the channels. Light andMethylene Bluewere employed
as a ROS-generating system (Fig. 1G). It is seen that the ROS-induced
inactivation of the gramicidin-mediated current could be prevented
by SkQ1 or MitoQ, SkQ1 being more effective. Similar relationships
were revealed when ascorbate, FeSO4, and tBOOH were used to
generate OH
U
[37,49].
Uptake of SkQs by mitochondria was monitored with a hydro-
phobic cation-sensitive electrode. Addition of a Δψ-discharging
uncoupler initiated partial release of SkQs to the medium, the effect
being larger with SkQ5 than with the more hydrophobic SkQ1 [37].
Next we tested whether SkQ1 and other plastoquinone deriva-
tives could be reduced by the animal mitochondrial respiratory chain
(Fig. 2A). Either NAD-linked substrates or succinate were found to be
used as electron donors. In both cases, reduction of SkQ1 was
completely arrested by antimycin A, myxothiazol being without
effect. The relationships may be explained assuming that SkQ1, like
plastoquinone [50–53], is reduced by endogenous CoQH2 bound in
center i of Complex III, localized in the inner leaﬂet of the inner
membrane. Oxidation of SkQ1H2 was found to be enzymatic (by
myxothiazol-sensitive Complex III of the respiratory chain) or non-
enzymatic (by either lipid radicals or O2). The overall rate of SkQ1H2
oxidation was lower than that of SkQ1 reduction by the respiratory
chain. This means that in respiring mitochondria SkQ1 should be
mainly in its reduced state that is competent in antioxidant activity
toward LO2
U
(see above, Eq. (1)) [37].
What are the relationships of the anti- and prooxidant effects of
SkQ1 and related substances on mitochondria? To estimate antiox-
idant activity, we used prevention by these compounds of malondial-
dehyde (MDA) formation initiated by Fe2+ and ascorbate in rat heart
mitochondria. As prooxidant action, we measured stimulation by the
same compounds of the H2O2 production in mitochondria oxidizing
glutamate andmalate in State 4. Fig. 2B shows that antioxidant activity
of SkQ1 is measurable at much lower concentration of this substance
than that of SkQ3 and especially of MitoQ, whereas prooxidant SkQ1
activity becomes observable at slightly higher [SkQ1] than [MitoQ]. As
a result, the window for the pure antioxidant effect not accompanied
bya prooxidant action appears to be verymuch larger for SkQ1 than for
MitoQ, SkQ3 occupying an intermediate position. SkQR1 proved to be
as active as SkQ1. Decylplastoquinone lacking a cation was even less
active thanMitoQ,whereas C12TPP lacking a quinone residuewas quite
inactive at the studied concentrations [37]. The prooxidant effect was
much smaller with C12TPP. Uncouplers as well as respiratory chain
inhibitors (rotenone and myxothiazol as well as cyanide) strongly
lowered the rate of H2O2 formation in the presence of micromolar
concentrations of cationic quinones [37].
As further analysis revealed, it is cardiolipin that is ﬁrst oxidized
under conditions of OH
U
generation by Fe2+ + ascorbate in heart
mitochondria. The amount of cardiolipin was strongly decreased after
Fe2+ + ascorbate treatment, the effect being signiﬁcantly lowered by
100 nM SkQ1 (Fig. 2C) [37].
This observation deserves special attention. As a matter of fact,
cardiolipin peroxidation appears to be a key event in mitochondrial
oxidative stress. (1) Cardiolipin is themost sensitive constituent of the
inner mitochondrial membrane to the ROS-induced peroxidation (see
above). This means that its peroxidation initiates chain reaction
“setting on ﬁre” other membrane constituents. (2) Cardiolipin
operates as an anchor for cytochrome c in the mitochondrial
membrane while oxidized cardiolipin fails to perform such a function
[54]. As a result, cytochrome c releases to the mitochondrial
intermembrane space and acquires cardiolipin-peroxidase activity,
initiating a vicious cycle of further cardiolipin peroxidation [55]. (4)
The loss of cardiolipin inactivates all the respiratory chain complexes,
H+-ATP-synthase, ATP/ATP-antiporter, etc., induces an increase in
permeability of the inner mitochondrial membrane and, as a
consequence, the collapse of Δψ, swelling of matrix, disruption of
the outer mitochondrial membrane, and release of cytochrome c and
Fig. 2. SkQ effects on isolated rat heart mitochondria. (A) Reduction of SkQ1 and oxidation of formed SkQ1H2 by isolated rat heart mitochondria. The reduction and oxidation were
measured by a decrease and an increase in optical density at 274 nm, respectively. Where indicated, 2.5 mM succinate with or without 2.5 mMmalonatewas added at zero time.1 μM
myxothiazol or 4mM glutamate and 1mMmalatewere added after 18min incubation. Rotenone (2 μM)was added at zero time in all samples except that with glutamate andmalate.
The medium contained 250 mM sucrose, 10 mM MOPS-KOH, 0.1 mM EGTA, pH 7.4, and mitochondria (0.05 mg protein/ml). (B) Anti- and prooxidant activities of SkQ1, SkQ3, and
MitoQ in isolated heart muscle mitochondria. Antioxidant activity was measured as inhibition of MDA formation initiated by adding 10 mM ascorbate and 100 μM FeSO4 to
mitochondria oxidizing 4 mM glutamate and 1 mMmalate (other components as in A). Prooxidant activity was estimated as stimulation of H2O2 formation under similar conditions
but without ascorbate and FeSO4. Colored bars below abscissa indicate windows between concentrations of given quinone derivative causing 20% anti- and 20% prooxidant effects.
(C) SkQ1 speciﬁcally protects mitochondrial cardiolipin from damage by OH
U
. A silicagel-60 chromatogram of mitochondrial phospholipids. Elution, chloroform:methanol:water,
65:25:4 (horizontal); chloroform:acetone:methanol:acetic acid:water, 6:8:2:2:1 (vertical). 1, cardiolipin; 2, phosphatidyl ethanolamine; 3, phosphatidyl choline; 4, phosphatidic
acid; 5, phosphatidyl serine; 6, phosphatidyl inositol; 7, lysophosphatidyl inositol.Where indicated,100 nM SkQ1was added. Other conditions as in B. (D and E) Effects of SkQ1, SkQ3,
MitoQ, and C12TPP on State 4 respiration (D) and membrane potential (E) of mitochondria. For conditions, see B. (From Antonenko et al. [37]).
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latter effect initiates apoptosis [56]. Thus, it is not surprising that the
prevention of cardiolipin peroxidation by SkQs results in strong
protective effects under conditions of oxidative stress inducing
apoptosis and necrosis (see below).In experiments on isolatedmitochondria, it was also found that the
hydrophobic cations used (SkQ1, SkQ3, MitoQ, and C12TPP) possess
some uncoupling activity. At concentrations 5×10−7–5×10−6 M,
they stimulate State 4 respiration and (at slightly higher concentra-
tion) lower Δψ (Fig. 2D and E, respectively). The mechanism of such
Fig. 3. Effects of SkQ1, SkQR1, and MitoQ on human cell cultures. (A) Co-localization of
SkQR1 (a ﬂuorescent SkQ derivative) and mitochondria-targeted jellyﬁsh yellow
ﬂuorescent protein fused with the leader sequence of cytochrome oxidase subunit VIII
(MitoYFP). HeLa cells were transfected with Mito-YFP (Clontech) and incubated for
15 minwith 100 nM SkQR1. Confocal microscopy. (B) SkQ1 and SkQR1 are more efﬁcient
than MitoQ in arresting H2O2-induced apoptosis in human ﬁbroblasts. Fibroblasts were
grown for 7 days with or without cationic quinones and then treated with 400 μM H2O2
for 24 h. (C) Preventive effects of SkQR1, SkQ1, and MitoQ on H2O2-induced ﬁssion of
elongated mitochondria. Human ﬁbroblasts were preincubated with SkQR1, SkQ1, or
MitoQ for 2 h and then treated with 400 μM H2O2 for 3 h. (From Antonenko et al. [37]).
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H+ conductance of the membrane, which was mediated by free fatty
acids. In BLMs, it was shown that the above cations induce high H+
conductance provided a fatty acid is added [Severina, I. I. et al., in
preparation]. Most probably, we deal here with the same phenom-
enon as was previously described for mitochondria treated with
tetraphenylphosphoniumwhich was shown to potentiate uncoupling
by fatty acids [57]. The mechanism was assumed to consist in
operation of a hydrophobic cation as a carrier for fatty acid anions,
which otherwise are of low penetrating ability. This effect together
with diffusion of protonated fatty acids (that penetrate well) in the
opposite direction can organize in a membrane a futile H+ cycle.
It should be stressed that uncoupling activity of SkQ can also be
involved in its antioxidant effect, especially if we deal with ROS
produced in the Complex III center o facing the intermembrane space
of the mitochondrion. Such ROS, in contrast to those produced by
Complex I inside mitochondria, are hardly quenched by SkQ1
concentrated in the inner leaﬂet of the inner mitochondrial mem-
brane. However, SkQ⋅fatty acid anion/SkQ antiport between the inner
and the outer leaﬂets, resulting in a Δψ decrease, can strongly lower
the rate of ROS generation not only in Complex I but also in Complex III
due to very steep dependence of this rate upon Δψ. Thus, a small Δψ
decrease (“mild uncoupling” [58]) was shown to induce manifold
decrease in ROS production [8]. One might suggest that the
uncoupling effect of hydrophobic cations mimics the mild uncoupling
by uncoupling proteins (UCPs), as well as by ATP/ADP, antiporter, also
mediated by fatty acids [59].
In this context, one may mention of another possible function of
minor UCPs (UCP2, 3, etc.) postulated by Dr. F. Goglia and one of us (V.
P.S.) [60], namely translocation of fatty acid peroxides from the inner
to the outer leaﬂet of the inner mitochondrial membrane, where they
are further metabolized by cytochrome c and some other enzymes. In
this way, mitochondrial DNA and other intramitochondrial systems of
great importance can be preserved under conditions when ROS are
produced by Complex I. It was found in our group [61] that fatty acid
peroxides are of much lower uncoupling activity than intact fatty
acids. This ismost probably due to low permeability of themembranes
even to their protonated forms [60]. Such an assumption explains why
fatty acid peroxides cannot organize a protonophoric cycle although
their anions are translocated by UCPs. If SkQ and C12TPP are also
competent in translocation of fatty peroxide anions, this should result
in irreversible extrusion of such anions from the mitochondrial
interior. These relationships are summarized in Table 1.
In the next part of the study, cell cultures were investigated. Herewe
started with an experiment showing intracellular localization of SkQ. To
this end, SkQR1, a ﬂuorescent SkQ derivative, was applied. SkQR1 was
found to be speciﬁcally accumulated by mitochondria of HeLa cells,
showing the same intracellular localization as mitochondria-targeted
jellyﬁsh yellow ﬂuorescent protein, YFP (Fig. 3A) or MitoTracker Green
(not shown). The SkQR1 staining of mitochondria inside the living cell
completed during 1 h, and subsequent incubation of the cells in a
medium without SkQR1 resulted in slow SkQR1 release (t1/2=2.5 h).Table 1
Four possible antioxidant effects of SkQ in mitochondria
N Effect Process Active
compounds
Source of
ROS
1 Reduction of inner LO2 LO2
U
+SkQH2→LOOH
+SkQ−.
SkQH2 Complex I
2 Oxidation of inner O2−U O2−
U
+SkQ→ O2+SkQ−
U
SkQ Complex I
3 Mild uncoupling by fatty
acid cycling
RCOO−ð ÞinYSkQ RCCO−ð Þout SkQ,
SkQH2,
C12TPP
Complexes
I and III
4 Extrusion of inner fatty acid
peroxides (LOOH)
LOOHð ÞinYSkQ LOOHð Þout SkQ,
SkQH2,
C12TPP
AnyUncoupler FCCP prevented the SkQR1 staining and stimulated its efﬂux
if added to non-stained and stained cells, respectively [37].
In further study, we asked whether SkQs possess antiapoptotic and
antinecrotic effects when cell death is induced by ROS. As the
experiments showed, SkQs prevented ROS-linked cell death. Espe-
cially low concentrations of SkQ1 and SkQR1 were effective when
human ﬁbroblasts were pre-treated with SkQs for a week before
initiation of apoptosis by H2O2 (following the protocol described by
Saretsky et al. [35] for MitoQ). In this case, 0.2 nM SkQ1 (Fig. 3B)
almost completely abolished apoptosis of human ﬁbroblasts, induced
by 400 μM H2O2. Dissipation of Δψ by the uncoupler FCCP prevented
the antiapoptotic effect of such a low SkQ1 concentration. The
protective effect of small amounts of SkQ1 could be overcome by
increasing [H2O2] to 500 μM (not shown) or [SkQ1] to 2×10−7 M.
High [SkQ1] stimulated the proapoptotic effect of H2O2 (Fig. 3B).
Moreover, it was found that low [SkQ1] prevented migration of
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chrome c release to cytosol in response to H2O2. Neither decylplas-
toquinone nor C12TPP at nanomolar concentrations could substitute
for SkQ1 [37]. In this context, it should be noted that prevention by
cationic quinones of endogenous oxidative stress in cell cultures was
ﬁrst observed by Murphy et al. on ﬁbroblasts from patients with
Friedreich's ataxia [36]. This disease is associated with a disorder in
production of the mitochondrial protein frataxin, which results in an
increase in the content of iron ions in the matrix and, as a
consequence, in oxidative stress. Such ﬁbroblasts can survive in
culture only in the presence of antioxidants, in particular, decylu-
biquinone (C1/2=3·10−8 M). MitoQ was much more effective than
decylubiquinone (C1/2=5·10−10 M; cf. in our experiments on
normal ﬁbroblasts, inhibition of H2O2-induced apoptosis by SkQ1,
C1/2=8·10−12 M [37]). In Murphy's experiments, an excess of
MitoQ (5·10−7 M and more) could not protect the ataxia cells
against oxidative stress, whereas an excess of decylubiquinone
(1·10−4 M) was as efﬁcient as its lower quantities [36].
Addition of small amount of H2O2 to HeLa cells was found to induce
a burst in endogenous ROS formation. This phenomenon described by
one of us (D.B.Z.) as a ROS-induced ROS release [62] was completely
abolished by pre-treatment of the cells with 20 nM SkQ1 [37].
Pre-treatment with very low [SkQ1] or [SkQR1] prevented
decomposition of mitochondrial ﬁlaments into small mitochondriaFig. 4. Effect of SkQ1 on mitochondrial morphology in HeLa cells. (A–F) Confocal and ele
treatment with 20 nM SkQ1. After 7 days, the cells were kept without (A–C, E) or with (D
(From Antonenko et al. [37]).(the “thread–grain transition”, an early consequence of the action of
apoptogens [63]). In this case, preincubation of ﬁbroblasts with the
cationic quinones for 2 h was sufﬁcient to observe the protective effect
(Figs. 3C, 4C–F), which increased as follows: MitoQbSkQ1bSkQR1.
Measurable activity was observed at 2×10−13 M SkQR1. An increase
in the quinone concentrations to 3×10−8 MMitoQ, 4×10−8 M SkQR1,
and 1×10−7 M SkQ1 abolished the protective action (Fig. 3C).
Without H2O2, low SkQ1 concentrations stimulated formation of
themitochondrial network (Fig. 4A,B). Local damage to this network by
a very narrow laser beam resulted in a Δψ collapse over the entire
mitochondrial reticulum, whereas without SkQ mitochondrial Δψwas
found to bedischargedmitochondria only in a small part of the cell [37].
This might be explained assuming that the SkQ1-induced decrease in
the level of endogenous ROS stimulates fusion of the majority of
mitochondria into an electrically-united mitochondrial reticulum [63].
In other experiments, pre-treatment of HeLa cell with 1 μM SkQ1
for 1 h arrested necrosis induced by illumination of cells stained by
MitoTracker Red as a photosensitizer. The C1/2 for this effect was
between 200 and 500 nM. Under the same conditions, a mixture of
1 μM TPP and 1 μM decylplastoquinone was inefﬁcient. NAC and
Trolox could substitute for SkQ1 but at very much higher concentra-
tions (20mM and 1mM, respectively). The data of this section suggest
that SkQs effectively operate as antioxidants at the cell level,
preventing ROS-induced apoptosis and necrosis [37].ctron microscopy, respectively. (A, C and D) Without SkQ1; (B, E and F) After 7 day
, F) 100 μM H2O2 for 6 h. A, B, Mitochondria were visualized with MitoTracker Green.
Table 2
Effect of in vivo SkQ1 treatment on stability of cardiac rhythm after 40 min perfusion of
isolated heart with 0.1 mM Н2О2 (from Bakeeva et al. [68])
SkQ1 dose,
nmol/
kg×day
Number
of
hearts
studied
Hearts with
normal rhythm
Hearts with
ﬁbrillation
Arrhythmia
index
Number % Number %
0 (control) 25 9 36 11 44 3.6±0.5
0.02 11 6 55 1 10 1.2±0.5⁎
0.2 22 16 72 4 18 0.8±0.5⁎⁎
2.0 11 7 64 1 10 2.7±0.9
250 10 3 30 4 40 4.6±1.1
Asterisks, statistically signiﬁcant (⁎pb0.05; ⁎⁎pb0.01) difference between the SkQ1 and
control groups.
Fig. 5. Preventive effects of SkQs on ischemia/reperfusion-induced damage to rat heart.
(A) Feeding of rats with SkQ1 during 3 weeks decreases the ischemia/reperfusion-
induced arrhythmia in isolated rat heart. (B) SkQ1 reduces myocardial infarction area in
rats in vivo. Control, 250 nmol NaBr/kg×day for two or three weeks (n=24); NaBr was
used since SkQ1 was a bromide salt; 1, 2.5 nmol SkQ1/kg×day for three weeks
(n=12); 2, 25 nmol SkQ1/kg×day for two weeks (n=11); 3, 125 nmol SkQ1/kg×day
for two or three weeks (n=9); 4, 250 nmol SkQ1/kg×day for three weeks (n=11); 5,
500 nmol SkQ1/kg×day for two weeks (n=10). ⁎pb0.05; ⁎⁎pb0.02 versus control.
(From Bakeeva et al. [69]).
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was measured in HeLa cells. It was found that this level is lowered
by adding H2O2, which pointed to development of oxidative stress.
This effect was prevented by SkQ1 and SkQR1, the C1/2 being about
2×10−12 M [37].
The efﬁciency of extremely low concentrations of SkQ1 and SkQR1
as antioxidants and antiapoptotic agents in experiments on cell
cultures is most probably due to cooperation of two factors. First, the
coefﬁcient of their distribution between the hydrophobic and aqueous
phases is very high: in the octanol/water system, it is 13,000 for SkQ1
[37]. Then, we gain three orders of magnitudemore due to the effect of
Δψ on the inner mitochondrial membrane (∼180 mV) and one order
more from the Δψ on the outer cell membrane (∼60 mV). In total, the
SkQ1 concentration gradient between the extracellular medium and
inner half-membrane layer of the inner mitochondrial membrane is
immense: 13,000×1000×10=1.3×108. This means that at the SkQ1
concentration in themediumof 1·10−12M, its concentration in the inner
half-membrane layer ofmitochondriawill be 1·10−12·1.3·108=1.3·10
−4M.On the way to the inner mitochondrial membrane, SkQ1 crosses
the outer cellular membrane, endoplasmic reticulum membranes,
and the outer mitochondrial membrane, being at ﬁrst accumulated
within them due to high lipid/water distribution coefﬁcient. In the
next step, SkQ1 goes to the inner mitochondrial membrane to be
distributed according to the Nernst potential [64].
Experiments on simple model systems, isolated mitochondria, and
living cells revealed some advantages of SkQs as antioxidants over
MitoQ. This was more apparent on mitochondria and especially cells
than on the model systems. Such relationships appear to be due to the
fact that in mitochondria and cells several favorable properties of SkQ
potentiate each other, resulting in the ﬁnal effect when SkQ is
manifold more active as antioxidant compared to MitoQ. The proper-
ties in question are the following.
(1) In aqueous solution, SkQ1 quenches OH
U
several times better
than MitoQ (Fig. 1C, D).
(2) In aqueous solution, SkQ1H2 is oxidized by O2 to form O2−U three
times slower than MitoQ (Fig. 1E, F).
(3) SkQ1 inhibits methyl linoleate peroxidation in micelles four
times stronger than MitoQ [37].
(4) In BLMs, SkQ1 protects gramicidin from being attacked by ROS
at three times lower concentrations than MitoQ (Fig. 1G).
(5) The afﬁnity of mitochondrial cardiolipin for SkQ1 was shown to
be 2.5 times higher than for MitoQ [37].
(6) SkQ1 is four times more hydrophobic than MitoQ [37].
(7) SkQR1 and SkQ1 cross the phospholipid bilayer ten and two
times faster than MitoQ, respectively [44].
3. Favorable effects of SkQs shown on heart arrhythmia, heart
infarction, stroke, and kidney ischemia
In further experiments, effects of in vivo SkQ treatments on some
common age-related pathologies of heart, brain, and kidney werestudied. All of them are shown to be accompanied by strong increase
in the ROS level [65–68].
Inparticular, the SkQ1 effectwas tested on isolated rat heart inwhich
an arrhythmia was induced by addition of H2O2 into the perfusate or by
ischemia/reperfusion. The arrhythmiawas signiﬁcantly lesspronounced
and ﬁbrillation was much less frequent if the hearts had been obtained
from rats pretreated for two weeks with SkQ1 (2·10−11 mol/kg×day)
(Table 2 and Fig. 5A). Increasing [SkQ1] to 2.5×10−7 M abolished the
favorable effect in the case of theH2O2-induced arrhythmia (Table 2). As
to that induced by ischemia/reperfusion, themaximal favorable effect of
SkQ1 was observed at 5×10−10 M, it decreased at 5×10−8 M, and
increased again at 2.5×10−7 M SkQ1 (Fig. 5A) [69].
A similar pretreatment of rats was employed in an in vivo model of
myocardial infarction. SkQ1 (2.5·10−7 mol/kg×day) decreased by 40%
the damaged zone of the heart muscle. This SkQ1 concentration was
much lower than that of MitoQ used by Murphy's group to normalize
contractile function andmitochondrial structure inheart after ischemia/
reperfusion [70]. Lower(b1×10−7mol)andhigher(5×10−7mol)SkQ1
doses were without measurable effect (Fig. 5B).
Activities of plasma lactate dehydrogenase (LDH) and creatine
kinase MB isoenzyme (CK-MB) activities did not signiﬁcantly differ
between the controls and SkQ1-fed groups in the steady state, a fact
indicating that SkQ1 supplementation at a dose of 250 nmol/kg×day
for two weeks did not damage the outer cell membranes. Myocardial
infarction was associated with a profound increase in both plasma
LDH and CK-MB activities at the end of reperfusion. These activities
were markedly reduced when rats were fed with SkQ1. Moreover, the
in vivo pretreatment with SkQ1 was found to partially prevent effects
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phosphate, and lactate as well as on the structural parameters of
cardiomyocytes (actomyosin ﬁbrils, Z-discs, and mitochondria) in the
infarction area. In numerous mitochondria, continuity of both the
outer and inner membranes disappeared, other mitochondria were
swollen, and matrix became transparent after ischemia/reperfusion.
These and some other pathological changes did not occur in hearts of
the SkQ-fed rats. In particular, no disrupted mitochondrial proﬁles are
seen. In fact, the only obvious effect of ischemia/reperfusion consisted
in this case in a decrease in the electron density of the mitochondrial
matrix space [69].
It should be mentioned that amount of SkQ1 effective in treatment
of arrhythmia was much lower than those or infarction (0.02–0.5 and
100–250 nmol/kg×day, respectively). Such a difference might be
explained by different localization and concentration of mitochondriaFig. 6. Effects of SkQR1 on rat kidney. A–J, Pharmacokinetics of SkQR1 distribution over kidney
SkQR1 to the inferior vena cava; B, C, 60 min after injection of 200 μl 1 mM SkQR1; D, E, 120 m
SkQR1. Bar, 50 μm. H–L, ROS generation in kidney slices detected by DCF ﬂuorescence. H,
reperfusion; J, kidney from a rat that received a single injection of 1 μmol SkQR1/kg×day be
but instead of SkQR1 the same concentration of MitoQ was injected. I–J, bar, 100 μm. I/R, isin pacemaker cells and cardiomyocytes that are the most probable
targets for SkQ1 in cases of arrhythmia and infarction, respectively. In
the former case, we are dealing with small cells and rather rare
mitochondria more or less equally distributed in various cell parts. In
the latter case, numerous mitochondria are concentrated below
sarcolemma of these very large cells, whereas the rest are localized
between actomyosin ﬁbrils, the cell being ﬁlled with much water-
insolublematerial (ﬁbrils, Z-discs, sarcoplasmic reticulum, etc.) which
might adsorb SkQs.
In other experiments, the effect of SkQs on kidney ischemia has
been studied. At ﬁrst, a culture of kidney epithelial cells was applied as
a model. It was revealed that preincubation with SkQ1 increases
survival of these cells after 24 h anoxia followed by 24 h reoxygena-
tion. Optimal concentrations of SkQ1 were between 10 and 250 nM. It
was also shown that SkQ1 prevented ﬁssion of elongatedcompartments after its intravenous injection. A,10min after injection of 300 μl of 1mM
in after injection of 200 μl 0.1 mM SkQR1); F, G, 3 days after injection of 200 μl 0.1 mM
control isolated kidney; I, isolated kidney after 40 min ischemia followed by 10 min
fore ischemia; K, average ROS production evaluated from 6 different experiments; L as K
chemia/reperfusion. (From Bakeeva et al. [69]).
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the anoxia/reoxygenation procedure [69,71].
In the next study, we followed the fate of SkQR1 in kidney slices
after either intravenous or intraperitonal injection of this compound
into rats. Fluorescence was clearly seen in glomerular zones of the
kidney 60 min after injection into the vena cava inferior (cf. Fig. 6A–
C). After 2 h, ﬂuorescence decreased in these regions with parallel
appearance of the ﬂuorescence in the kidney tubular epithelial cells
(Fig. 6D, E). In three days, further accumulation of SkQR1 in
epithelium and complete loss of ﬂuorescence in glomerular zones
took place (Fig. 6F, G). Incubation of a kidney slice taken from a rat
120 min after intraperitoneal injection of SkQR1 in the presence of
mitochondrial ﬂuorescent dye (MitoTracker Green) revealed co-
localization of the two dyes in the kidney cells [69].
On isolated kidney, a 40 min ischemia followed by reoxygenation
resulted in a strong increase in the ROS level detected by DCF
ﬂuorescence in kidney slices. Earlier we demonstrated that this
elevated DCF ﬂuorescence originated frommitochondria [72]. A single
intraperitoneal injection of SkQR1 (1 μmol/kg) to the animal a day
before ischemia partially normalized the ROS level (Fig. 6). Injection ofFig. 7. Effects of SkQR1 (1 μmol/kg, intraperitoneally injected a day before 90 min ischemia) o
parameters of kidney functioning. A, diuresis (ml/day); B, blood creatinine (μM), C, blood urea
single-kidney rats exposed to 90 min kidney ischemia followed by reoxygenation. SkQ1 or SkQthe same amount ofMitoQ did not decrease the ROS level. SkQ1 caused
some decrease which, however, was statistically insigniﬁcant [69].
Some markers reporting on the distortion of the kidney function
after ischemia/reoxygenation are presented in Fig. 7A–E. These
experiments were done on animals having a single kidney (the
other has been removed before the ischemia). This model recently
applied, e.g., by Serviddio et al. [73], was chosen to put higher load on
the kidney function since the single-kidney ischemia in animals
carrying two kidneys was shown to be without lethal effect on the
organism. In the case of single kidney experiments, there was an
obvious beneﬁcial action of SkQR1. Partial normalization of diuresis,
blood [creatinine], and Ca2+ reabsorption took place, facts showing
that this compound protects to a certain degree the kidney tissue from
damage induced by ischemia/reperfusion. A single-kidney ischemia
(90 min) followed by reoxygenation was extremely traumatic to the
whole organism. The majority of rats died during the ﬁrst six days
after this kind of treatment. However, a preventive single injection of
SkQR1 or SkQ1 a day before ischemia almost totally abolished the
death of the experimental animals (Fig. 7F). The rats stayed alive for at
least half a year after ischemia [69].n kidney functioning and survival of rats after kidney ischemia in single-kidney rats. A–E,
(mM); D, glomerular ﬁltration rate (ml/min×kg); E, Ca2+ reabsorbtion (%). F, Survival of
R1 were intraperitoneally injected a day before the ischemia. (From Bakeeva et al. [69]).
Fig. 8. Protective effect of SkQR1 against brain damage induced by compressive brain
ischemia. SkQR1 treatment, single intraperitoneal injection of 1 μmol SkQR1/kg one day
before the experiment. (A and B) pariental and frontal parts of the rat brain, respectively.
Numbers of animals in A and B, 19 and 13, respectively. (From Bakeeva et al. [69]).
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hemorrhagic insult by application of a load to a certain brain area
[74]. This model simulates the situation in the brainwhen the outﬂow
blood is released into the brain cavity as a result of a hemorrhagic
insult, causing the pressure on the certain areas of the brain and, as a
consequence, an ischemia. Analysis of serial 100 μm brain sections
revealed severe damage to the tissue that could be decreased by
intraperitonial injection of SkQR1 (0.5 or 1 μmol/kg) a day before
compressive ischemia (Fig. 8). Treatment with 0.5 μmol SkQ1/kg
failed to substitute for SkQR1 [69]. One may speculate that SkQR1 as
better penetrant than SkQ1 more easily reaches brain.
Favorable effect of SkQR1 on neurons could be related to inhibition
of the ROS-induced apoptosis by this antioxidant. It was found that
SkQR1 protects primary culture of rat cortical neurons against H2O2-
induced apoptosis. The optimal SkQR1 concentrationwas 100 nM [69].
4. SkQ1 inhibits tumor development in p53-deﬁcient mice
As discussed above, an increase in oxidative stress is a key factor of
the aging process. Moreover, it is known that elevation of ROS plays an
important role in development of tumors (reviewed in [75,76]). Such
relationships may be at least partially responsible for strong increase
with age in occurrence of cancer. In fact, moderate rise of the ROS
content, which per se does not kill a cell, leads to enhanced DNA
oxidation and, as a result, to genetic instability and accumulation of
oncogenic mutations in proto-oncogenes, tumor suppressor genes,
and some other genes, causing neoplastic cell transformation and/or
further tumor progression [75,76,79]. In addition, changes in level of
ROS which function as secondary messengers in many signal
transduction pathways affect cell proliferation, migration, and
viability that also contribute to tumorigenesis [77,78,80–82]. It is
noteworthy that 1.5–3-fold increase in intracellular ROS concentration
represents an important component of oncogenic effects of such
genomic alterations typical for human neoplasms as inactivating
mutations of the tumor suppressor p53 or activating mutations of RAS
and MYC proto-oncogenes [79,82–87]. NAC and some others anti-
oxidants were shown to (i) mitigate genetic instability caused by the
p53, Ras, and Myc malfunctioning [83–85]; (ii) decrease growth rate
of Ras-transformed cells [86]; (iii) diminish the intensity of Ras-
induced morphological transformation and cell motility [82]; (iv)
inhibit ROS-dependent tumor angiogenesis induced by Ras and p53
dysfunctions [87,88] or by some other oncogenic events [78,89]. As a
result, development of tumors (in particular, in transgenic mice with
p53 gene knockout (p53−/−) [83,90] or with Myc protein super-
production [91]) was shown to signiﬁcantly delay.
In this part of the study, we asked whether mitochondria-targeted
antioxidant SkQ1 affects tumor development. For this purpose, we
used two approaches: (i) analysis of the effect of diet supplementation
with SkQ1 on spontaneous development of tumors (prophylacticactivity), and, (ii) a study on the inﬂuence of SkQ1 on progression of
already formed tumors (therapeutic activity). In the ﬁrst case, we used
mice with homozygous p53 gene knockout [92,93] resulting in ROS
up-regulation [83]. In the second part of the work, we studied the
growth of xenografts of a set of human carcinomas with different
status of p53 tumor suppressor. Investigations of various p53
abnormalities was done because (i) a p53 malfunctioning represents
the most universal molecular alteration in various human tumors
(reviewed in [90,94–96]) whose oncogenic effect is at least partially
dependent on attenuation of antioxidant defense [83,90,96]; (ii)
several types of p53 abnormalities are characteristic for human
tumors, includingmissense-mutations leading to synthesis of proteins
which fail to perform the wild-type p53 functions but acquire quite
other activities [94,95]. In particular, we studied xenografts of HCT116
colon carcinomas (a) expressing wild-type p53, (b) expressing p53
proteins with amino acid substitutions in positions 248 and 273which
represent the hot-spots of mutations in colorectal cancers, or (c)
showing loss of p53 expression due to homozygous p53 gene
knockout. In addition, we analyzed xenografts of SiHa human HPV-
16-associated cervical carcinoma in which p53 functioning is
mitigated due to its interaction with E6 viral oncoprotein. Finally,
we studied SkQ1 effects on tumor cells cultured in vitro to understand
possible mechanisms of inhibitory inﬂuence of SkQ1 on growth of
some types of tumors [97].
To study possible anti-oncogenic potential of SkQ1 we, ﬁrst,
studied effect of diet supplementation with various SkQ1 doses on
tumor appearance in the p53−/− mice. Such mice show increased
levels of ROS [83] and are highly predisposed to the spontaneous
development of a variety of neoplasms starting at about three months
of age. The predominant types of malignancy are T- and B-cell
lymphomas (70–90%) [90,91]. We found that 5 nmol SkQ1/kg×day
caused about twofold decrease in intracellular level of ROS in mouse
tissues, in particular in spleen cells [97]. In mice receiving this dose of
SkQ1, the tumor development was delayed and the lifetime of animals
was increased by approximately 30–40% (Fig. 9A). In fact, 50% death
for p53−/− mice obtaining or not obtaining SkQ1 occurred on days
250 or 180, respectively. Effect of SkQ1 on the early death was
especially demonstrative. On day 185, about 60% of the p53−/− mice
without SkQ1 had died, whereas not a single animal died among those
who obtained SkQ1 (Fig. 9A). Such effect of extremely low dose of
SkQ1 was comparable with the effect of very much (more than
1,000,000-fold!) higher dose of conventional antioxidant NAC
(6 mmol/kg×day) used in our previous studies [83,90] (conﬁrmed
in the experiment shown in Fig. 9A). Lower (0.5 nmol/kg×day) and
higher (50 nmol/kg×day) SkQ1 dosages were less effective in tumor
prevention (Fig. 9B).
In the next series of experiments, we studied the effect of SkQ1 on
growth of xenografts of human tumors in immunodeﬁcient athymic
mice. For this purpose, we used tumor cells differing in the p53 status.
In particular, we studied a set of derivatives of HCT116 colon carcinoma
mimicking all situations observed in human colon cancers, i.e. the cells
expressing wild-type p53 protein, cells with simultaneous expression
of wild-type and dominant-negativemutant p53 proteins, and full loss
of p53 expression. All the HCT116 cell derivatives with abnormal p53
expression/function showed some increase in ROS levels as compared
with the original HCT116 cell line expressing wild-type p53 protein.
Supplementation of the diet with 5 nmol SkQ1/kg×day caused
certain, but statistically non-signiﬁcant, inhibition of the growth of
HCT116 tumors expressing the wild-type (Fig. 9C) or mutant (not
shown) p53 proteins. The inhibitory effect of the used SkQ1 dosage on
the growth of HCT116/p53−/− xenografts was more prominent and
statistically signiﬁcant. This case is shown in Fig. 9D. Surprisingly, the
xenografts of HCT116/p53−/−derivativewhich expressed additionally
the R248W mutant p53 protein showed lower sensitivity to growth-
suppressive effect of SkQ1, although such cells practically did not differ
from original HCT116/p53−/− cells in intracellular ROS level (not
Fig. 9. Effect of SkQ1 on the lifespan of p53−/−mice (A, B) or athymic mice with SiHa xenographs (F), on growth of the HCT116/p53+/+ (C) and HCT116/p53−/− (D) human colon
carcinoma xenografts or the SiHa human cervical carcinoma xenografts (E) in athymic mice. SkQ1 was added to the drinking water. A, B, Control p53+/+ mice (30 animals), control
p53−/− mice (17 animals), and p53−/− mice received 0.5 nmol SkQ1/kg×day (32 animals), 5 nmol SkQ1/kg×day (11 animals), 50 nmol SkQ1/kg×day (19 animals), or 6 mmol
NAC/kg×day (26 animals). A log–rank test comparing the group of non-treated p53−/− mice and the groups treated with 5 nmol SkQ1/kg×day or 6 mmol NAC/kgxday showed
two-sided distribution, pb0.005. (From Agapova et al. [97]).
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of the multidrug resistance pump in cells of different p53 status. As
shown in experiments with ﬂuorescing SkQR1, this cation is extruded
from the cell by the pump, the process being more effective in p53
R248W mutant cells than in wild type or p53−/− [97].
In addition, we found that the lifespan of the SkQ1-treated tumor-
bearing immunodeﬁcient mice increased as compared with control
SkQ1-untreated animals even in those cases when the treatment with
SkQ1 showed no signiﬁcant effect on the growth rate of tumor
xenografts. For example, diet supplementation with 50 nmol SkQ1/
kg×day did not inhibit at all the increase in volumes of SiHa human
cervical carcinoma xenografts but signiﬁcantly delayed the death of
such animals (Fig. 9E, F).
As it was found earlier in our group, antioxidant NAC lowered
the growth rate of HCT116 xenografts mainly through the inhibition
of tumor angiogenesis (tumors treated with NAC showed about
twofold decrease in the number of typical blood microvessels and
2–3-fold increase in the number of underdeveloped vessels without
lumens) [88]. This is why we decided to study effect of SkQ1 on
tumor angiogenesis. We found that SkQ1 inhibited angiogenesis in
vivo in a model of subcutaneous Matrigel implants. When injected
intraperitoneally, SkQ1 signiﬁcantly decreased the load of implants
with blood as well as the content of small blood vessels in Matrigel,the effect being observed only at highest dose of SkQ1 used
(10 μmol/kg×day, 10 days). The content of relatively large (N40 μm)
vessels was strongly decreased even at 0.1 μmol SkQ1/kg×day.
Angiogenesis in Matrigel implants depends on invasion of the
endothelial cells (or their precursors) and further development of
the blood vessels. The latter process could be strongly controlled by
transcription factor HIF-1α which was activated (stabilized) under
hypoxic conditions [98]. It was recently shown by Chandel, Murphy
et al. that stabilization of HIF-1α under hypoxia is mediated by ROS
produced in mitochondria of endothelial cells since this effect is
inhibited by MitoQ [99]. Our data suggest that in vivo maturation of
the vessels is suppressed by low doses of SkQ1 while their invasion
was less sensitive to our antioxidant.
Immunohistochemical analysis of HCT116/p53−/− tumor xeno-
grafts has shown that, similar to treatment with NAC, supplementing
diet with 5 nmol SkQ1/kg×day caused about twofold increase in the
number of underdeveloped lumen-free blood vessels but, unlike NAC,
caused only minor, statistically non-signiﬁcant decrease in the
number of typical vessels with lumens.
To learn more about possible mechanisms responsible for SkQ1-
induced inhibition of growth of xenografts, we studied how SkQ1
affects the cell culture in vitro. First, it was found that SkQ1 is able to
inhibit the rate of the tumor cell proliferation. In fact, the HCT116/
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culture after incubation with 5–50 nM of SkQ1 for 5–7 days. A
similar effect was observed in other tested cell cultures, in particular
in SiHa cells [97].
The HCT116/p53−/− cells do not show normal epithelial type of
cytoskeletal organization. Treatment of these cells with SkQ1 caused
restoration of epithelial features (Fig. 10A). Actin cytoskeleton became
more organized and ﬁlaments at the cell periphery and at cell–cell
contacts were well pronounced. Immunostaining of E-cadherin
revealed formation of prolonged E-cadherin-positive contacts. As a
result, the cells treated with SkQ1 formed typical epithelial islets in
culture, which were absent in untreated cells.
We also studied several epithelioid cell lines originated from
carcinoma of uterine cervix (CaSki, SiHa, C4I, HeLa). These cells
contain the wild-type p53 but show deregulated p53-dependent
signaling due to infection with papilloma viruses HPV16 or 18 and
interaction of viral E6 oncoprotein with p53. One of these cell lines,
SiHa (contains integrated HPV16), was studied in detail. These cellsFig. 10. Actin ﬁlaments and E-cadherin-positive intercellular contacts in HCT116/p53−/− (A)
7 days). (A) immunostaining with speciﬁc antibodies; (B) Western blot analysis. (C) Reversa
with 20 nM SkQ1 for 7 days. Immunostaining of actin ﬁlaments and vinculin-positive focalshowed disorganized system of actin ﬁlaments and the absence of
organized intercellular E-cadherin-positive contacts. Treatment with
SkQ1 increased the total amount of E-cadherin (Fig. 10B) and restored
actin bundles and well-organized intercellular contacts of SiHa cells.
Morphology of these cells and their islets became almost indis-
tinguishable from normal keratinocytes. The morphology of non-
transformed keratinocyte line HaCat was not signiﬁcantly affected by
SkQ1. Phenotype reversion (restoration of the normal epithelial-like
morphology) by SkQ1 treatment was observed also with other
carcinoma cell lines (CaSki, C4I, and HeLa). Of note, the well known
carcinoma HeLa, which is strongly dedifferentiated and has lost
almost all epithelial features, became organized in a more epithelial
fashion after treatment with SkQ1 [97]. Our data are in line with
previously published results on NAC-induced apical–basolateral
differentiation of colon and ovary carcinoma cell lines [100].
The effect of SkQ1 on transformed ﬁbroblasts was studied in
mouse ﬁbroblast cell line 10(3) with deleted p53. These cells can be
considered as minimally transformed cells. They are non-tumorigenic, and amount of E-cadherin in SiHa (B) before and after treatment with SkQ1 (40 nM for
l of the Ras-induced morphological transformation in 10/3 mouse ﬁbroblasts incubated
adhesion contacts. Bar, 20 μm. (From Agapova et al. [97]).
451V.P. Skulachev et al. / Biochimica et Biophysica Acta 1787 (2009) 437–461and retain basic morphological features of normal ﬁbroblasts [101].
The cells were dramatically changed upon transformation by
oncogene N-RasAsp13. Transformation was accompanied by great
decrease in the cell area. A major feature of cell transformation
during malignization consists in the loss and/or reorganization of
actin structures, which leads to enhanced cell motility and invasion
[102]. Ras induced dissipation of actin stress ﬁbers and related
vinculin-positive focal adhesions. This effect can be caused, at least in
part, by inactivation of the Rho-ROCK-LIMK signaling pathway
mediating coﬁlin phosphorylation and stress ﬁber formation [103].
We recently showed that ROS up-regulation is critical for Ras-induced
modulation of coﬁlin activities responsible for reorganization of cell
architecture and actin cytoskeleton [82]. Treatment of the Ras-
transformed cells with SkQ1 caused restoration of normal ﬁbroblastic
morphology, i.e., re-appearance of the stress ﬁbers and vinculin focal
adhesion contacts, and strong enlargement of cell area (Fig. 10C).
Similar phenotypic reversionwas observed in the SkQ1-treated SV40-
transformed human ﬁbroblasts MRC5-V2 [97].
Concluding this section, the data presented above clearly demon-
strate that SkQs do not possess a cancerogenic activity. Even more,
SkQ1 showed an anticancer effect at least in cells deﬁcient in p53, i.e.,
in a situation typical for many kinds of the human cancerogenesis. In
fact, we found that SkQ1 suppressed spontaneous tumorigenesis in
p53−/− mice as well as HCT116/p53−/− tumor xenograft growth in
athymic mice. These relationships can be accounted for assuming that
mitochondrial ROS-mediated apoptosis, which is speciﬁcally inhibited
by SkQs does not participate in the anticancer defense. Rather,
mitochondrial ROS are cancerogenic, so their scavenging by SkQ1de-
creases probability of malignization.
5. SkQ treatment of eye diseases. SkQ1 returns vision to blind
animals
Retina is in fact a tissue with the highest risk of ROS-induced
damage since (i) it contains a high level of polyunsaturated fatty acids,
a very good target for ROS, (ii) it is exposed to light producing such
kind of ROS as singlet oxygen and (iii) oxygen concentration in retina is
near-arterial, i.e., much higher than in the great majority of other
tissues (in spite of the fact that retina is a tissue of very high respiratory
activity) [104]. There are numerous indications of the crucial role of
ROS in themain age-related ocular pathologies, i.e. retinopathies (such
as maculodystrophy [105,106], retinitis pigmentosa [107,108], heredi-
tary optic neuropathy [109]), glaucoma [110,111], cataract [112,113],
and uveitis [114,115]. Polyunsaturated fatty acids in mitochondrial
cardiolipin are ﬁrst of all attacked bymitochondria-produced ROS that
are quenched by SkQs [37]. This is why the above-listed pathologies
attracted our attention as a possible ﬁeld of therapeutic application of
SkQs. Below we shall describe some results obtained when animals of
various ages, suffering from retinopathies, cataract, uveitis, glaucoma,
and some other eye diseases were treated with SkQ1 [116].
We studied the therapeutic effect of SkQ1 on cataract and
retinopathies, using OXYS rats, a strain suffering from constant
oxidative stress. In these rats, cataract and retinopathy appear as
early as at 2.5–3 months age [117,118].
In the ﬁrst series of experiments, it was found that levels of lipid
peroxidation (estimated by measuring MDA) and oxidation (carbo-
nylation) of proteins are higher in skeletal muscles of one year old
Wistar rats than in three month old ones. The effect of age was even
larger in OXYS rats. Feeding with very low amounts of SkQ1 (50 nmol/
kg×day) resulted in a decrease in the lipid and protein oxidation
levels. The mineral mass levels in vertebra and extremities were lower
in OXYS than in Wistar rats due to senile osteoporosis. Again, SkQ1
feeding was favorable, increasing the mineral mass in OXYS rats [116].
Thus, the above data showed that SkQ1 is competent in preventing
some consequences of oxidative stress in OXYS rats. Then an attempt
was undertaken to treat eye diseases in these animals with SkQ1. Asexperiments showed, addition of the above-mentioned SkQ1 amounts
to the food completely prevented development of cataract and
retinopathy in OXYS rats up to age of two years (Fig. 11A–C, Table 3).
The above conclusion concerning preventive effect of SkQ1 on
24 month old OXYS rats was conﬁrmed by histological analysis of
sections across the retina (Fig. 11D–F). The ﬁgures show that in an old
OXYS rat without SkQ1 treatment, the photoreceptor layer is absent,
whereas an OXYS rat receiving SkQ during all its life retained this
layer. In old Wistar rats the photoreceptor layer was present even
without SkQ. These results are in line with our observations that the
electroretinogram disappeared in the majority of the 24 month old
OXYS rats but was retained in OXYS rats with SkQ1 as well as inWistar
rats (Fig. 11C, Table 3).
Vitamin E was much less efﬁcient that SkQ1. Even 500 μmol
vitamin E/kg×day (i.e. 10,000–fold higher than SkQ1) decreased the
cataract and retinopathy levels far less than SkQ1. It is remarkable that
the SkQ1 effects were not accompanied by any induction of
cytochromes P450 in liver, in contrast to those of vitamin E [116].
It was also found that instillations of drops of nanomolar SkQ1
signiﬁcantly reverse pathological changes in middle-age OXYS
animals (Fig. 11G, H). The latter effect was also observed in Wistar
rats suffering from cataract. In very old (24 months) rats, neither
cataract nor retinopathy was reversed by SkQ1 (although SkQ1 still
effectively prevented the diseases, see Fig. 11A–F).
Reversal of an already developed retinopathy by SkQ1 drops was
conﬁrmed by electron microscopy. It was shown that retinopathy in
11-month-old OXYS rats results in obliteration of choriocapillaries.
This parameter is at least partially normalized after a 1.5-month
course of instillations of 250 nM SkQ1 (one drop daily). Reappearance
of choriocapillaries in the presence of SkQ1 was accompanied by
normalization of some other morphological features, i.e., distribution
of lipofuscin granules in retinal pigmented epithelial cells and
disappearance of hernias formed due to disruption of Bruch's
membrane [116].
Favorable effects of SkQ1 can disappear when it is added in excess.
In skeletal muscles of OXYS rats, this occurred at 250 nmol SkQ1/
kg×day. In bones of the same rats, 250 nmol SkQ1was still as effective
as 50 nmol. In eyes of OXYS rats, drops of 10 nM–1 μM SkQ were
effective in reversal of cataract and retinopathy, 5 μM being ineffective
(Fig. 11G,H). As to eyes of Wistar rats, even 25 μM SkQ was still of
favorable activity. These relationships can be explained assuming that
(i) disappearance of therapeutic action of SkQ is due to prooxidant
activity of its high concentrations [37] in OXYS rats suffering from
oxidative stress, and (ii) the intrinsic antioxidant status of Wistar rats
is much better compared with OXYS rats, so these rats are better
defended against prooxidant effect of high [SkQ1].
In the same OXYS rats, it was found that SkQ1 feeding prevents a
premature age-dependent decline of the immune system, namely
involution of the thymus and a decrease in the area occupied by
primary follicles in spleen (Fig. 11I and J, respectively).
In another series of experiments, uveitis was induced by
immunization of a rabbit with a photoreceptor-speciﬁc protein,
arrestin, which resulted in blindness. This effect was prevented and
reversed by SkQ1 instillations (four drops of 250 nM SkQ1 per day)
[116]. It was also found (Fig. 11K) that the same SkQ1 treatment
strongly inhibited formation of NO2− and NO3− in eyes of the uveitis-
suffering animals (under uveitis, these processes are known to be
initiated by interaction of NO and O2−U, which are superproduced in the
retina of the uveitis-suffering animals [119]).
Experimental glaucoma was also studied in rabbits. The disease
was induced by a series of the instillations of 2% hydroxypropyl
methyl cellulose to the eye anterior sector. This resulted in
appearance of such typical glaucoma features as increase in
intraocular pressure (Po), a strong decrease in the aqueous humor
outﬂow (C), as well as in humor production (F), a rise of Bekker's
coefﬁcient (BC), and some increase in the lens thickness. Analysis of
Fig. 11. Effects of SkQ1 on animal eye diseases (A–H and K, L; from Neroev et al. [116] and on age-dependent involution of thymus (I, J) (from Obukhova et al., in preparation). SkQ1
prevents development of cataract (A) and retinopathies (B, D–F) in OXYS rats. C, electroretinograms of three OXYS rats: 3 months, no SkQ1; 24 months, no SkQ1 and 24 months,
250 nmol SkQ1/kg×day with food. Flash, 3 cd·s/m2. G, H, Therapeutic effect of various SkQ1 concentrations upon already developed cataract and retinopathies in OXYS rats. The
treatment (one drop of SkQ1 solution daily) was started when rats were 9 months old. Drops of SkQ1 were instilled during 52 days. In each group, 24 eyes of 12 animals were studied.
I and J, SkQ1 prevents an age-dependent decrease in cellularity of the right lobe of the thymus and in area occupied by the spleen follicles, respectively. When indicated, 3.5-month-
old rats received 250 nmol SkQ1/kg×daywith food. #, p, 0.05. A histological study of sections across the retina of 24-month-oldWistar (D) and OXYS (E, F) rats. F, OXYS rats obtained
SkQ1 with food from age 1.5 months (250 nmol/kg×day). Staining with hematoxylin and eosin. D, Wistar rats; normal retina structure is well seen, i.e. (1) rods, (2) outer nuclear
layer, (3) outer plexiform layer, (4) inner nuclear layer, (5) inner plexiform layer, and (6) ganglionic cell layer. E, OXYS rats without SkQ1; there is no photoreceptor compartment
(rods as well as outer nuclear and plexiform layers are absent). F, OXYS rats with SkQ1; all the layers are present. D–F, bar, 50 μm. K, SkQ1 prevents an experimental uveitis-induced
increase in the nitrite and nitrate levels in the aqueous humor of the eye interior sector. Twenty eyes (10 rabbits) were studied, namely, 6 eyes without and 14 eyes with SkQ1(four
drops of 250 nM SkQ1 were instilled daily during 33 days). L, Electroretinograms of the left eye of a dog suffering from an inherited retinal dysplasia. Where indicated, one drop of
250 nM SkQ1 was instilled daily during 27 or 42 days. The dog was blind before the SkQ1 treatment. After the treatment, vision returned.
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Table 5
Therapeutic effect of instillations of Vetomitin (drops of SkQ1) on retinopathies
Animal
species
Number of animals
Before treatment After treatment
Blind Partial loss
of vision
Total Vision was returned
to blind animal
Vision was
improved
Vision was
not improved
Dog 58 19 77 46 19 12
Cat 27 9 36 17 5 14
Horse 4 18 22 4 18 0
Total 89 46 135 67 42 26
From Neroev et al. [116].
Table 6
Therapeutic effect of instillation of Vetomitin (drops of 250 nM SkQ1) on uveitis,
conjunctivitis and cornea diseases
Table 3
Effect of SkQ1 added to food (250 nmol/kg×day) on the b-wave magnitude of the rat
electroretinogram
Strain OXYS Wistar
Age (months) 3 24 24 3 24 24
SkQ1 − − + − − +
b-wave, μV 56±3 19±13 42±9 54±11 37±9 55±12
From Neroev et al. [116].
Standard errors are indicated.
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Pathologic changes of all these parameters were prevented by
instillation of drops of 5 μM SkQ1 solution. Higher SkQ1 (25 μM)
was less efﬁcient than 5 μM SkQ1 (Table 4).
Finally, an attempt was undertaken to apply SkQ1 in cases of
veterinarian practice when conventional medical treatments failed. A
total of 135 animals (dogs, cats, and horses) suffering from various
retinopathies were treated daily with drops of 250 nM SkQ1. In 89
cases, the animals were completely blind before the treatment. Vision
was returned to 67 of them (Table 5). There was not a single case
when SkQ1 had an unfavorable effect or its efﬁciency declined in the
course of the treatment time.
Electroretinograms of a dog whose visual function was recovered
by means of 250 nM SkQ1 instillations are shown in Fig. 11L. The dog
was blind because of inherited retinal dysplasia. As the ﬁgure shows,
before the SkQ1 treatment there was practically no electric response
to light. After 27 days of SkQ1 instillations, visual function was
partially recovered and some electric response appeared. Even larger
response was revealed on day 42 of the treatment, which was
accompanied with further improvement of vision [116].
Among dogs, cats, and horses suffering from retinopathies were
those with inherited retinal dysplasia (degeneration), progressing
retinal degeneration, or a secondary retinal degeneration. The best
results of SkQ1 treatment were obtained with inherited dysplasia (a
positive effect in 67% cases) and secondary degeneration (in 54%
cases). As to progressing degeneration, SkQ1 helped in 29% cases.
Moreover, SkQ1 was effective in some cases of dry eye syndrome as
well as for treatment of uveitis and some other autoimmune eye
diseases, conjunctivitis, and certain corneal diseases (Table 6). Drops
of SkQ1 were without effect on neuro-ophthalmological pathologies.
It should be mentioned in this context that an attempt to treat
inherited retinopathies by a mitochondria-targeted antioxidant was
recently undertakenbyWright et al. [120]. TheyusedMitoQand failed to
obtain any positive result. The reason for this might be small size of the
window between anti- and prooxidant concentrations of MitoQ [37].
6. SkQ1 prolongs lifespan and retards senescence
In the ﬁnal series of experiments, we tried to inhibit by SkQ1 the
senescence program of different organisms. We started with short-
lived species, namely the mycelial fungus Podospora anserina, aTable 4
Drops of 5 μM SkQ1 prevent development of experimental glaucoma in rabbits
Group Parameter Lens thickness,
mm
P0 C F BC
Control 17.4±0.7 0.16±0.02 1.28±0.26 108±24.2 7.3±0.08
Glaucoma 19.6±0.8⁎ 0.05±0.01⁎ 0.38±0.13⁎ 387±47.4⁎ 7.9±0.14⁎
Glaucoma+
5 μM SkQ1
16.5±0.8 0.14±0.04 2.5±0.49⁎ 117.2±27.6 7.5±0.08
Glaucoma+
25 μM SkQ1
22.5±1.0⁎ 0.10±0.04 2.0±0.43 224.6±39.2⁎ 7.8±0.21⁎
From Neroev et al. [116].
⁎ pb0.05 for the eye with experimental glaucoma vs. normal eye.crustacean Ceriodaphnia afﬁnis, and an insect Drosophila melanogaster
[121].
During the last decade, the fungus P. anserina has become the
subject of interesting experiments on regulation of lifespan. In
particular, this parameter can be signiﬁcantly changed experimentally
by affecting mitochondrial respiration, morphology, and ROS forma-
tion [122,123]. This is why we started the gerontological part of the
project with studies on P. anserina.
As experiments showed (Fig. 12A), low (100 nM) SkQ1 added to
the agar medium increases the lifespan of P. anserina. SkQ1 was
especially effective at early stages of aging, e.g., on day 21, 70% of the
fungi die without SkQ1 and only 25% with SkQ1. The median lifespan
was increased by 50% by SkQ1. The difference decreased with age so
that lifespan of the last 10% of fungi was increased by only 20%. Higher
(1 μM) and lower (20 nM) SkQ1 concentrations were less effective
than 100 nM. The effect of SkQ1 was accompanied by retardation of
development of such traits of mycelial aging as appearance of brown
color and disappearance of protrusions of mycelium to the air phase
(aerial mycelium) [121].
The crustacean C. afﬁnis is a convenient subject for lifespan
research since its imago life cycle is usually as short as 15–20 days
and cultivation under laboratory conditions is not a problem. One
more advantage is that the concentration of SkQ1 affecting the
living subject could be exactly estimated since C. afﬁnis can live in
aqueous solutions of SkQ1 of known dilution. Fig. 12B shows that
5.5 and 0.55 nM SkQ1 increase the C. afﬁnis lifespan, whereas
55 nM SkQ1 has an opposite effect. The median lifespan at the
optimal (0.55 nM) SkQ1 concentration was doubled compared with
the samples without SkQ1 [121].
D. melanogaster is an effective model system for gerontological
studies due to its reasonably short lifespan and the possibility to use
genetically well characterized lines. Our experiments showed that
SkQ1 prolonged lifespan of ﬂies, though the effect was not as strong as
in C. afﬁnis. The food with supplemented SkQ1 (three drops of 20 pM
SkQ solution coated to the food surface weekly) proved to be effectiveAnimal species Total Positive effect No change
Uveitis
Dog 26 23 3
Cat 8 8 0
Horse 19 19 0
Total 53 50 3
Conjunctivitis
Dog 32 32 0
Cat 15 15 0
Horse 5 5 0
Total 52 52 0
Cornea diseases
Dog 31 31 0
From Neroev et al. [116].
Fig. 12. Effect of SkQ1 on lifespan of fungus Podospora anserina (A) and of crustacean
Ceriodaphnia afﬁnis (B). In A, 100 nM SkQ1 was used. In B, ethanol solutions of different
SkQ1 concentrations were added to the growthmedium, ethanol being diluted by factor
of 1,000. Addition of the same amount of ethanol without SkQR1 did not affect lifespan.
(From Anisimov et al. [121]).
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20 pM and 20 nM SkQ1.
Detailed analysis of the effect of SkQ1 on lifespan of females
revealed that it is more pronounced at early stages of life. As seen in
Fig. 13A, mortality during the ﬁrst 10 days of life was almost
completely abolished by 20 pM SkQ1, whereas during the ﬁrst
20 days SkQ1 decreased mortality by only 30%. At higher ages, the
effect of SkQ1 became even smaller. This phenomenon is also
illustrated by Fig. 13B where mortality rate is presented in half-
logarithmic coordinates as a function of age. It is evident that SkQ1
effect was at its maximum for the ﬁrst 10 days, when mortality was
decreased by one order of magnitude. A mixture of 20 pM solution
of TPP and PQ, two constituents of SkQ1, was completely ineffective
[121].
Fig. 13C–E summarizes results of experiments when the SkQ1
treatment was carried out during certain stages of life rather than
during the entire lifespan. Fig. 13C shows that the survival curve of
ﬂies fed with SkQ1 during the ﬁrst week of life did not differ from the
survival curve of ﬂies constantly obtaining SkQ1 till death (p=0.75),
whereas both were signiﬁcantly different from the control curve
(p=0.0004 and pb0.0001). Such a short-term SkQ1 treatment was
ineffective when started on the 30th day (Fig. 13D). However, constant
SkQ1 feeding from the 30th day till the end of life was effective (Fig.
13E, p=0.0025) [121].
20 pM C12TPP, a compound containing two additional methylene
groups instead of plastoquinone in SkQs, was also found to increaseFig. 13. SkQ1 increases the lifespan of Drosophila melanogaster. A and B, SkQ1 affects life
respectively). A total of 425 females per treatment were analyzed, 20 pM SkQ1 or mixture of
or constantly, starting from the 30th day (E) increases lifespan of females as does SkQ1 fe
ineffective (D). From 225 to 425 females per treatment were analyzed. On C and E, survival c
p=0.0025, correspondingly). [SkQ1], 20 pM. F, 20 pM C12TPP, a SkQ analog lacking the q
treatment were analyzed. C12TPP and SkQ1 survival curves are signiﬁcantly different from
related ultrastructural changes in the D. melanogaster ﬂight muscles. G, 1.5-day-old ﬂy. H, 5
prevents appearance of age-dependent damage to mitochondria (“mitochondrial swirls”). Mthe lifespan of ﬂies. However, substantial difference in effects of SkQ1
and C12TPP was revealed. SkQ1, as already mentioned, primarily
affected young females, whereas C12TPP was practically ineffective in
young ﬂies but was effective later in life. As a result, the C12TPP
survival curve followed the control curve during the ﬁrst 20 days,
while during the last 40 days it followed the SkQ1 curve (Fig. 13F),
being signiﬁcantly different from control curve (pb0.0001) [121]. As
was recently found in our group (see above), hydrophobic cations
such as SkQs and C12TPP can operate as carriers of fatty acid anions,
mediating in this way mild uncoupling of oxidative phosphorylation
by these acids. This, in turn, should decrease the ROS production not
only by Complex I but also by Complex III [37].
Fig. 13G–I show the effect of SkQ1 on mitochondrial ultrastruc-
ture in ﬂight muscles of D. melanogaster of different ages. In line
with data of Walker et al. [124], we found that aging is accompanied
by appearance of organelles of dramatically changed structure
(membrane multilayers resembling myelin). Such structures called
“mitochondrial swirls” [124] were absent from very young (1.5 days)
ﬂies but appeared as early as on the 10th day of life. The
mitochondrial swirls were usually integrated into chains of mito-
chondria localized between bundles of actomyosin ﬁlaments. In the
SkQ1-fed ﬂies, damaged organelles were still very rare even on the
65th day (Fig. 13I).
In this context, it should be noted that the idea concerning
mitochondrially-targeted quinones as geroprotectors was introduced
by Murphy et al. [125] and simultaneously by one of us (V.P.S.) [126].
In Murphy et al. [127], an attempt was undertaken to prolong the
lifespan of D. melanogaster with MitoQ. No geroprotective effect was
observed on wild-type ﬂies. MitoQ was effective only on females of a
short-lived mutant that was deﬁcient in mitochondrial superoxide
dismutase and showed several traits of progeria. We also tried 20 pM
MitoQ and observed some geroprotective effect even inwild type ﬂies.
The effect was smaller than with SkQ1 and could be revealed only on
early ages. As to the median lifespan, it changed insigniﬁcantly. It
seems possible that for such a post-mitotic organism as a ﬂy, mean
lifespan is not a sensitive trait to reveal potential geroprotectors. It is
remarkable that the geroprotective effect of SkQ1 was much more
pronounced when the amount of damaged muscle mitochondria was
measured [121].
Two long-term experiments were performed to reveal the effect
of SkQ on the lifespan of outbred SHR mice. One of them was
started in December, 2004, and another in June, 2005. In each
experiment, there were four groups of females (25 animals in each
group): one group for control mice (not-treated with SkQ1), and
three others for mice receiving with drinking water 0.5, 5, or
50 nmol SkQ1/kg×day. The results of both experiments are
summarized in Fig. 14A. One can see that all the SkQ1 concentra-
tions used signiﬁcantly prolonged the lifespan, the middle (5 nmol)
concentration being optimal. Moreover, like in the above-described
experiments on fungi and invertebrates, the effect was especially
strong on initial and middle stages of life rather than on maximal
lifespan which increased only slightly (so-called rectangularization
of the survival curve). With the optimal SkQ1, the median lifespan
was found to double. For mammals, such a strong shift of the
survival curve to the right is a very rare case. On day 300, more than
50% of control mice had already died, whereas in the group of
5 nmol SkQ1 almost all animals were still alive [121].span mainly at early stages of life (cumulative percent of death and mortality rate,
20 pM TPP and 20 pM PQ being employed. C–E, SkQ1 fed during the ﬁrst week of life (C)
d during entire life, whereas SkQ1 fed during one week starting from the 30th day is
urves of SkQ1-treated females are signiﬁcantly different from control curves (pb0.0001,
uinone part, increases lifespan of D. melanogaster females. A total of 425 females per
the control curve (pb0.0001 in both cases). G–I, Effect of SkQ1 on mitochondrial age-
2-day-old ﬂy. Insert shows a multimembrane structure at high magniﬁcation. I, SkQ1
ales; SkQ1, 1.85 nM. (From Anisimov et al. [121]).
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Fig. 14. SkQ increases lifespan and prevents appearance of traits of senescence in mice. (A) The ﬁgure summarizes results of two experiments on the lifespan measurement of 200
females. In each experiment, four groups of females (25 mice in each group) were studied. (B) Age-dependent mortality of mice for reasons other than tumors. (C) SkQ1 prevents
disappearance with age of regular estrous cycles. (D) 630-day-old mice receiving (right photo) and not receiving (left photo) 0.5 nmol SkQ1/kg×day. (E–G) Some properties of
ﬁbroblast obtained from tails of mice receiving or not receiving SkQ1. (E) spontaneous and H2O2-induced apoptosis. (F) percentage of β-galactosidase-positive cells. (G) percentage
of cells with phosphorylated histone H2AX. (From Anisimov et al. [121]).
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increase in lifespan is mainly due to strong lowering of rate of the
death caused by diseases other than cancer (Fig. 14B). Most of these
were infections, such as pneumonia, hepatitis, nephritis and colitis,
which were a consequence of the fact that the mice were living under
non-sterile conditions. This made it possible to take into account
probable preventive effect of SkQ on an age-dependent decline of the
immune system (for preventive effect of SkQ1 on involution of thymus
and spleen in OXYS rats, see above, Fig. 11 I, J).
Prevention of decline of immunity proved to be not the only
geroprotective effect of SkQ1 on rodents. In particular, it was shown
that SkQ1 completely prevented disappearance of regular estrous
cycles in the outbred SHR mice (Fig. 14C). In Fig. 14D, photographs of
two 630-day-old female mice, one receiving a minimal dose of SkQ1
(0.5 nmol/kg×day) and another without SkQ1, are presented. It
seems obvious that themousewithout SkQ1 is in bad shape comparedwith that with SkQ1. The animal has lost whiskers and showed
obvious traits of baldness and lordokyphosis. We also found that
torpor and a body temperature decrease during the last weeks of life
observed in mice not treated with SkQ1were not pronounced in the
SkQ1-treated mice. As to food and water consumption and body
weight, they did not signiﬁcantly differ in all the mouse groups
studied, so the SkQ effect cannot be explained by a caloric restriction.
In the last series of experiments on the SHR mice, ﬁbroblasts
obtained from the tails of the control and SkQ1-fed animals of various
ages were studied. It was found that spontaneous apoptosis of
ﬁbroblasts from old control mice occurs three times more often than
in young animals. This difference disappeared if mice received 0.5, 5,
or 50 nmol SkQ/kg×day. Fibroblasts from mice which received SkQ1
retained the ability to activate apoptosis by added H2O2, but the effect
of H2O2 was not as strong as in ﬁbroblasts from untreated mice of the
same age (Fig. 14E). It was also shown that the in vivo SkQ1 treatment
2 Imagine two hares, a clever one and a stupid one, being chased by a fox. If the
hares are young, their muscles are strong, and they will both easily escape the fox.
When the hares become older, they will be affected by muscle wasting as a sign of
aging, and they will run slower. However, the clever hare will probably start running
before the stupid one, and has more chances of surviving and producing clever
leverets. This is how aging may be advantageous for natural selection [2].
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β-galactosidase activity and phosphorylated histone H2AX (Fig. 14F
and G, respectively).
7. Discussion: mitochondria-targeted plastoquinone derivatives as
potential tools to prolong youth
Experiments on model systems, mitochondria, and living cells in
vitro have conﬁrmed the suggestion that conjugates of penetrating
cations with plastoquinone (SkQs) are much better antioxidants
than those with ubiquinone (MitoQ) [37]. As a result, the window
between anti- and prooxidant effects of SkQs is much broader than
that of MitoQ. Experiments on rats showed that in vivo SkQ
treatment prevents development of pathological changes of several
age-related diseases. It strongly lowers ischemia/reoxygenation-
induced arrhythmia and prevents ﬁbrillation of hearts isolated from
animals, decreases damaged area of heart after infarction and of
brain stroke, and prevents death after kidney ischemia [69]. In p53
−/− mice, SkQ1 or NAC increase the lifespan, SkQ1 being effective at
106 times lower concentration than NAC [97]. On rats, rabbits, dogs,
cats, and horses, instillation of SkQ drops into eyes has favorable
effect on retinopathies, cataract, glaucoma, and uveitis, the major
kinds of aging-induced eye diseases [116]. Nano- or even picomolar
concentrations of SkQ1 increased lifespan of fungus P. anserina,
crustacean C. afﬁnis, insect D. melanogaster, and mice. In the latter
case, 5 nmol SkQ/kg×day doubled the median lifespan. This was
accompanied with disappearance of numerous typical features of
senescence, i.e. the loss of estrous cycles and whiskers of females,
baldness, decrease in body temperature, torpor, lordokyphosis,
osteoporosis, etc. Some aspects of the age-dependent decline of
the immune system did not occur [121]. Moreover, our experiments
suggest that sexual motivation of males, long-term memory, high
rate of wound healing, and normal blood pressure are retained in
old animals receiving SkQ1 (Kolosova, N. Medvedeva, N. and
Skulachev, V., in preparation). SkQ1 prevented development of
canities which accompanies an X-ray-induced progeria in black mice
(Ryazanov, A., in preparation). Moreover, SkQ1 abolished age-
dependent decrease in lymphocytes and increase in neutrophils in
mice (Shipunova, I. et al., in preparation). At the biochemical level, it
was revealed that SkQ1 prevents such age-induced processes as
peroxidation of lipids and proteins, stimulation of apoptosis,
appearance of β-galactosidase activity, and phosphorylation of
histone H2AX [121].
The geroprotective effects of SkQ1 could be accounted for within
the framework of alternative concepts considering aging as a result of
(i) accumulationwith age of occasional injuries and (ii) operation of a
speciﬁc genetic program of slow suicide (for reviews, see [2,6]). In the
former case, SkQ1 simply “cleans the dirtiest place in the cell”,
removing from the mitochondrial interior those ROS that are
responsible for age-related injuries [126]. In the latter case, SkQ
prevents execution of an aging program which slowly kills organisms
bymeans of intramitochondrial ROS, the level of which increases with
age in a program-controlled fashion. At present, we cannot discrimi-
nate between these two possibilities. However, there are several
indirect but independent pieces of evidence making the program
scheme more probable.
(1) In experiments with D. melanogaster, we found that SkQ1
treatment during the ﬁrst week of life has the same geroprotective
effect as treatment during the whole life (Fig. 13C). This result is, in
fact, in line with the observations that (i) two days caloric restriction
of the fruit ﬂy prolongs the lifespan of the ﬂy as effectively as caloric
restriction during the whole life [128] and (ii) just odor of the food
decreased the caloric restriction effect upon lifespan of D. melanoga-
ster [129]. These ﬁnding can be explained much more easily by a reset
of the “ontogenetic clock” controlling the aging program than by the
assumption that SkQ1 or caloric restriction directly prevent accumu-lation of ROS-induced (or any other) injuries. In this context, one
might suggest that the age-controlling “ontogenetic clock” system
operates in a mitochondrial ROS-dependent fashion so that the target
of the geroprotective action of SkQ1 is, in fact, mitochondria of the
clock cells or of any other cells involved in execution of the clock
signals.
(2) ROS-induced injuries are known to be accumulated in
especially large quantities at late age. Therefore, one might expect
that SkQ1 would be more effective toward the end of life. In our
experiments, we observed, however, quite opposite relationships.
SkQ1 prevented age-dependent death at early and middle stages of
aging, being only slightly efﬁcient in increasing the maximal lifespan
(see Figs. 12–14). This observation ﬁts the hypothesis that the aging
program is a mechanism increasing “evolvability” (the rate of
evolution), assuming that aging allows natural selection to recognize
small useful traits that are insufﬁcient for a strong young organism but
become signiﬁcant when its functions decline with age [2,7,20,22]2.
Very old organisms (i) compose a small part of population and (ii)
their reproductive potential is already lowered so that their contribu-
tion to the evolvability process should be limited. This means that in
such organisms, the aging program becomes unnecessary for evolu-
tion and therefore hardly contributes to the senescence process.
(3) The last but not the least, one should take into account the
suggestion concerning SkQ1 as a geroprotector proved to be a
consequence of a hypothesis on programmed aging. In such a
complicated science as biology, the very fact that hypothesis predicts
a set of experimental results is always an argument in favor of its
validity.
Within the framework of the concept considering aging as an
evolvability-increasing invention of living organisms, it seems
obvious that many functions of vital importance should decline
with age. As a result, evolution of all of them can be accelerated by
aging. This is why there are numerous senescence processes which,
after all, cause the death of the organism and why effect of SkQs is
so pleotropic. As to non-aging organisms, they may die due to a
single reason, and their life is not accompanied by decline of many
physiological functions.
As already mentioned above, Brand et al. [9] reported that the
lifetime of mammals and birds is longer the lower is the rate of
H2O2 generation inside heart mitochondria during the reverse
electrons transfer through Complex I. The longest-lived African
rodent, the naked mole-rat, was the only exception to this rule. This
creature of mouse size is famous for its lifespan of about 28 years
instead of the mouse's 2.5–4 years. Cancer, atherosclerosis, immu-
nodeﬁciency and some kinds of pain are unknown for this animal.
The queen and her several sexual partners, the only reproducing
members of the large community composed of 200–300 soldiers,
have, in fact, no enemies. In the laboratory, naked mole-rats die at
age of about 25–28 years for an unknown reason. Their mortality
rate does not depend on age [130], as if the aging program is absent
in this animal. The program seemed to be switched off somewhere
downstream of ROS because both the rate of ROS generation on the
reverse electrons transfer [9] and the level of biopolymer oxidation
[131,132] in naked mole-rats are higher than in mice. The latter
ﬁnding is not surprising since activities of superoxide dismutase and
catalase in these two species are of the same order of magnitude,
while the third main antioxidant enzyme, glutathione peroxidase, is
70-fold less active in naked mole-rats than in mice [133]. The key
for understanding of this paradoxical situation seems to consist in
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apoptosis in cultured arteria of naked mole-rat [134]3. In this
respect, the mole-rat is reminiscent of long-lived mice with
mutations in genes encoding the protein p66shc [137], the enzyme
of CoQ synthesis mClk1 [138], or elongation factor 2 kinase (A.G.
Ryazanov et al., in preparation), whose cells are also resistant to
apoptogenic action of hydrogen peroxide or the prooxidant
menadione.
A possible mechanism explaining how a function that became
unnecessary for naked mole-rats could disappear during evolution
was recently described by Park et al. [139]. It was found that these
rodents lack an 11 amino acid peptide called substance P, which
operates in other animals as mediator of certain kinds of the pain
signal (in particular, of the pain caused by capsaicin, a compound from
capsicum). Capsaicin, like several other pain-inducing factors, does
not induce a pain response in the naked mole-rat. The sensitivity to
capsaicin was restored when a herpes-containing DNA construct
encoding the substance P-synthesizing enzymewas injected into a leg
of the animal. The treatment did not affect pain sensitivity of the
untreated legs. Most probably, the naked mole-rat queen and her
mates are so perfectly defended by the army of soldiers in the center of
their underground labyrinth that external pain-causing events are
practically excluded. As a result, a mutation making impossible
transmission of the pain signal proved to be functionally neutral and
therefore avoided elimination by natural selection. The same
apparently happened with the program of aging which, according to
our hypothesis, requires enemies to operate as an evolution-
accelerating mechanism.
It is of importance that SkQ1 concentrations increasing lifespan
seem to abolish the aging-induced stimulation of apoptosis rather
than completely arrest any ROS-linked apoptotic events (Fig. 14E).
This is apparently why doses of SkQ1 used in our experiments onmice
did not decrease antitumor defense, which includes apoptosis. In fact,
SkQ1, like another antioxidant, NAC, prolonged lifespan of a mouse
strain prone to lymphomas [97].
It is remarkable that SkQ1 strongly decreases the death risk for
reasons other than cancer (Fig. 14B). The reasons in question were
numerous infections inevitable in the non-sterile vivarium where the
experiments were carried out. This allowed us to reveal SkQ1 as a tool
arresting development of such a typical feature of aging as decline of
the immune defense of the organism4. Such a decline is due to
numerous factors including decrease in number of the antigen-
presenting dendrite cells (DC), impairment of chemotaxis and
phagocytosis of these cells and neutrophils, failure of DC to properly
stimulate naive CD4+ T cells, some functional injuries in monocytes,
decrease in the production and proliferation of normal killer cell, etc.
(for review, see [140]). Importantly, a decline in the immune system
represents one of the earliest traits of aging, starting in humans at an
age before 20 [141].3 Quite recently, a paper by Salmon et al. appeared [135]. The authors reported that
very low proapoptotic activity of H2O2 of naked mole-rat cells may be a tissue-speciﬁc
feature. An H2O2 resistance observed in cultured arteria is not the case for culture of
isolated ﬁbroblasts that are, in fact, more H2O2-sensitive in mole-rat than in mouse.
Alternatively, it seems possible that the low H2O2 sensitivity might be detected at the
level of a naked mole-rat tissue rather than isolated cells. As was quite recently shown
in our group ([37] and B.V. Chernyak et al., in preparation), addition of H2O2 to a cell
culture results in a burst of production of endogenous H2O2 in few hours after the
addition. This H2O2 can be released from the cell to induce apoptosis in bystander cells.
The latter effect is prevented by adding catalase [136] or by release of catalase from
damaged cells. Such a damage may be less frequent for mole rat ﬁbroblasts that are
more stable to many injuries [135]. In line with the above explanation, sensitivity to
prooxidant paraquat proved to be lower in ﬁbroblasts from mole-rat than from mouse
[135].
4 Quite recently, Dr. K.A. Rogovin in our group started studying the effect of SkQ1 on
lifespan of rodents that are kept in cages outdoors. This is done to model conditions of
the wild nature which are not only non-sterile but also include large temperature
ﬂuctuations (the main reason of death of small wild rodents in Russia is pneumonia in
the winter).One of the reasons for decline of the immune system during aging
is related to age-dependent involution of the thymus, the major
source of T-cells. Progeria in OXYS rats is accompanied with more
rapid decrease of the mass, volume, and cellularity of the thymus than
in normal rats (Obukhova, L.A. et al., in preparation). The right lobe of
the thymus in OXYS rats contains two times less cells than in Wistar
rats at 3.5 months of age. Treatment with 250 nmol SkQ1/kg×day
resulted in 2.5-fold increase of this amount in OXYS, while in Wistar
the increase was only 25%, so this parameter became equal in the two
strains of rats. A similar effect was observed when the area of
lymphoid follicles in the spleen (the major source of B-cells) was
analyzed (Fig. 11I, J).
Above we listed many crucial traits of senescence which are
retarded, arrested, and in certain cases even reversed by SkQ1. The
question arises why the SkQ-treated living creatures die in spite of
obvious deceleration of the senescence program. The simplest
explanation is that SkQ1 fails to arrest age-linked decline of at least
one physiological function of vital importance. Another possibility is
that the aging program does not operate in very old organisms who
die due to accumulation of occasional injuries (as was already
mentioned, very old organisms are not interesting for evolution
since they are too rare and their reproductive systems have declined).
Apparently, to live much longer than usually, one needs some “skill”. P.
anserina represents an interesting example in this context. This fungus
seems to employ two scenarios for life, one short-lived (several
weeks) and another very long-lived (years). Switching from the
short- to long-lived modus vivendi can be achieved by substituting a
liquid growth medium for a solid one [142]. A similar switch can be
observed also in P. anserina growing on a solid medium if mutations in
respiratory chain or mitochondrial morphology transition machinery
takes place [122,123]. The effect of SkQ1 on the short-lived fungus was
measurable but much smaller than the switch to the long-lived
scenario. In fact, P. anserina responded to SkQ1 like three other species
tested (C. afﬁnis, D. melanogaster, andmice), i.e., by 1.5–2-fold increase
in the median lifespan and by rectangularization of the survival curve.
These relationships can be explained assuming that in P. anserina
SkQ1 inhibited execution of the aging program but did not induce a
switch to the very long-lived modus vivendi.
Something similar was recently observed in Dr. B. Cannon's group
who tested, within the framework of our project, the action of SkQ1 on
progeric Larsson's “mutator mice” with the D257A mutation in the
proof-reading domain of mitochondrial DNA polymerase γ. Such a
mutant polymerase can synthesize DNA but cannot recognize and
repair its own errors in the process of this synthesis. As a result,
frequency of mutations in mitochondrial DNA increases, entailing
strong shortening in the lifespan and premature development of
numerous traits of senescence [143,144]. It was found that SkQ1
prevents or retards appearance of such senescence traits as lordoky-
phosis, baldness, lowering of body temperature, torpor, cessation of
the estrous cycles, etc., and increases the lifespan, but not so strongly
as is necessary to return it to the wild type level. Again, as in the
above-described wild-type mice, the SkQ1-receiving animals usually
die without showing a senescence scenario. The most probable reason
for death of the SkQ1-treated “mutator mice” is pathological changes
in the colon epithelium, a disease speciﬁc for mice with mitochondrial
mutations [145]. It should be noted that Cannon's experiments were
done on animals living in sterile vivarium. Generally, the effect of SkQ1
under these conditions resembled very much that on wild-type mice
in the non-sterile vivarium used in the experiments described in this
paper. The only difference was that infections were absent from
reasons of death of “mutator mice” (Shabalina, I. G. et al., in
preparation).
In conclusion, highly effective, mitochondria-targeted, recharge-
able antioxidants composed of plastoquinone, hydrocarbon linker,
and a penetrating cation (SkQs) have been synthesized and tested
on model membranes, isolated mitochondria, cell cultures, ex vivo
459V.P. Skulachev et al. / Biochimica et Biophysica Acta 1787 (2009) 437–461organs, and living organisms. It has been shown in experiments on
the fungus Podospora, invertebrates Ceriodaphnia and Drosophila,
and mice that SkQ1 increases the lifespan at very much lower
concentrations than previously known geroprotectors. This effect is
accompanied by rectangularization of survival curve and (in mice)
disappearance or retardation of many crucial traits of senescence. In
mice, an increase in the lifespan is ﬁrst of all due to prevention of
the age-dependent decline of the immune system. It is suggested
that SkQ1 is competent in switching off a senescence program
responsible for a concerted decline with age of key physiological
functions. Thus, this small molecule looks promising for elaborating
a drug prolonging youth.
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